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ABSTRACT 
 
Maria M. Aleman: Cellular and Plasma Protein Crosstalk in Arterial and Venous Thrombosis 
(Under the direction of Dr. Alisa Wolberg) 
 
 
Coagulation is an enzymatic cascade culminating in the formation of a clot.  
Intravascular coagulation is termed thrombosis.  Studies using platelet-rich plasma, whole 
blood, and animal models reveal the complex crosstalk between clotting factors and the 
cellular environment that promote thrombosis.  Three distinct, yet related, studies included in 
this dissertation exemplify this crosstalk.   
First, the vascular bed-dependent prothrombotic effects of elevated prothrombin were 
examined.  We found that elevated prothrombin increased venous, but not arterial, 
thrombosis in mice. The prothrombotic effects of elevated prothrombin were manifested by 
increased fibrin deposition but no significant increase in platelet accumulation.  These data 
show that elevated prothrombin would not be expected to contribute to platelet-dominated 
arterial thrombosis. 
Second, the procoagulant properties of microparticles from different cell types were 
investigated.  We found that monocyte-derived microparticles contributed to initiation and 
propagation of clotting via the extrinsic coagulation pathway, while platelet-derived 
microparticles contributed to primarily to propagation of clotting via the intrinsic coagulation 
pathway.  These data suggest monocyte-derived microparticles may contribute to the 
initiation of a thrombotic event, while platelet-derived microparticles may propagate an 
existing thrombotic event. 
 iv 
Third, the role of fibrinogen and factor XIII (FXIII) in venous thrombosis was 
studied.  We discovered the binding site of FXIII on fibrinogen, the necessity for FXIII 
activity for red blood cell retention in clots, and that reduction or deficiency of FXIII activity 
reduces venous thrombus size.  These data indicate a novel role for FXIII in the pathogenesis 
of thrombosis and implicate FXIII as a novel therapeutic target. 
Together, these studies emphasize the importance of complementary in vitro and in 
vivo studies of coagulation and thrombosis to properly elucidate the pathophysiological 
relevance of clotting factor and cell function. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1  Coagulation & Blood Cells 
 Blood coagulation is a complex enzymatic cascade culminating in the formation of a 
fibrin protein meshwork that turns liquid blood into a gel-like solid.  Two initiating 
coagulation pathways—intrinsic and extrinsic—converge on a common pathway that 
produces the serine protease thrombin (Figure 1.1).  Thrombin activates platelets and cleaves 
fibrinogen into fibrin monomers that polymerize into fibers forming a net-like structure that 
is stabilized by the transglutaminase factor XIII (FXIII). Misbalance of this system leads to a 
failure of hemostasis (bleeding) or excessive clotting (thrombosis). 
Clotting can be reduced down to two essential components—thrombin and 
fibrinogen. However, physiologic coagulation involves the entire cascade and, importantly, 
anionic phospholipid surfaces such as on an activated platelet.  Thus, the simple coagulation 
cascade has evolved into a cell-based model1 that emphasizes the role of blood cells in 
initiation or propagation of coagulation (Table 1.1).  Platelets, when activated, support 
coagulation by expression of anionic phosphatidylserine (PS) on their plasma membrane, 
release of granules rich in clotting factors such as factor V and fibrinogen, and by their 
ability to aggregate and occlude vessels at sites of trauma or atherosclerotic plaque rupture.2 
Leukocytes, such as monocytes and neutrophils, contribute to coagulation by various means: 
a) expression of tissue factor (TF)—the key initiator of extrinsic coagulation—can be 
induced following activation of monocytes3,4, and (mouse) neutrophils5, b) formation of  
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Figure 1.1.  Simplified coagulation cascade.  Extrinsic and intrinsic coagulation converge 
on the common pathway that activates prothrombin (II) to thrombin (IIa).  Thrombin then 
converts fibrinogen into fibrin and activates FXIII. Chapter 2 examines the effects of 
elevated prothrombin levels in mouse models of arterial and venous thrombosis.  Chapter 3 
examines the contribution of TF-bearing microparticles and non-TF-bearing microparticles to 
thrombin generation.  Chapter 4 investigates the relationship between fibrin(ogen), FXIII, 
and thrombus formation. Abbreviations:  TF, tissue factor; XII, factor XII; Xa, activated 
factor X; Va, activated factor V; II, prothrombin; IIa, thrombin; ATIII, antithrombin III; 
TAT, thrombin-antithrombin complex; XIII, factor XIII. 
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microparticles, especially TF-bearing microparticles6-8, and c) by neutrophil extracellular 
trap-mediated activation of the intrinsic coagulation pathway9,10.  Endothelial cells contribute 
to clotting by release of von Willebrand Factor which binds platelets11,12, their ability to bind 
fibrin and modulate its network structure13, and by induced expression of TF14, though their 
ability to express it in vivo is controversial15. Finally, red blood cells (RBCs) contribute to 
coagulation by exposure of PS that supports thrombin generation16,17, and RBCs increase 
blood viscosity18 and marginate platelets toward the endothelium19, placing them in close 
proximity to sites of vascular trauma.  Lastly, recent studies from our laboratory indicate 
RBCs directly dictate the size of clots (Chapter 4). 
 
1.2  Arterial & Venous Thrombosis 
 Thrombosis is a pathologic process leading to inappropriate intraluminal blood 
coagulation that is a key component of myocardial infarction, ischemic stroke, and venous 
thromboembolism (VTE; deep vein thrombosis (DVT)/pulmonary embolism (PE)). 
Cardiovascular disease (CVD), which includes myocardial infarction and ischemic stroke, 
currently afflicts 83.6 million Americans, caused 32.3% of all deaths in the United States in 
2009, and costs an estimated $312.6 billion each year.20 One million Americans suffer from 
VTE each year21, and incidence rates increase with age in both men and women20.  The 
annual health care costs for VTE, including hospital-acquired and recurrent events, are 
estimated to range from $15.4 to $34.4 billion.22  These pathologies are significant health and 
economic burdens and the need for improved understanding and treatment is essential. 
 Thrombosis can occur in different vascular beds—arterial or venous.  Arterial 
thrombosis is associated with atherosclerotic plaque rupture and exposure of highly  
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Table 1.1.  Procoagulant Properties of Blood Cells & Microparticles 
Procoagulant 
Property 
 
Platelets 
 
Leukocytes 
 
RBCs 
 
Endothelial 
Cells 
 
Microparticles 
Clotting 
Factor 
Expression 
Granules 
contain FV, 
fibrinogen 
Inducible TF  Inducible TF, vWF TF 
Anionic 
Phospholipids PS PS PS PS PS 
Aggregation 
or Adhesion 
Aggregation 
& plug 
formation 
Adhesion to 
EC 
Aggregation, 
adhesion to 
EC 
Supports 
adhesion 
Adhesion to 
other cells 
Other Binds fibrin(ogen) 
Neutrophil 
Extracellular 
Traps 
Viscocity, 
blood 
margination 
Binds 
fibrin(ogen)  
 
Abbreviations:  EC, endothelial cells; FV, factor V; PS, phosphatidylserine; TF, tissue factor; 
vWF, von Willebrand factor. 
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procoagulant sub-endothelial material and cells (Figure 1.2).23  This process occurs under 
high shear leading to the formation of platelet-rich thrombi—so called “white clots”—and 
detrimental vascular occlusion.  Treatment of arterial thrombosis primarily involves anti-
platelet drugs, sometimes with anticoagulation, and/or thrombolytic therapy.  Risk factors for 
arterial thrombosis include CVD, hypertension, diabetes mellitus, obesity, and smoking.24 
 Venous thrombosis, in contrast, is thought to originate in the hypoxic environment of 
venous valve pockets (Figure 1.3).25,26 In these areas, zones of blood flow recirculation lead 
to endothelial activation, leukocyte accumulation and activation, and the exposure of tissue 
factor and release of neutrophil extracellular traps thereby initiating coagulation and the 
formation of a thrombus rich in RBCs and fibrin—so called “red clots.”  Treatment for acute 
DVT is heparin, followed by warfarin for 3 to 6 months. Novel anticoagulants to replace 
warfarin include anti-Xa and anti-thrombin drugs. Like arterial thrombosis, risk factors for 
venous thrombosis include CVD, hypertension, diabetes mellitus, obesity, and smoking, but 
additional risk factors include trauma, infection, immobility, and cancer.27  The differences 
between arterial and venous thrombosis triggering events, cellular compositions, treatments, 
and risk factors highlight the context-dependent nature of coagulation in vivo. 
 
1.3  Hyperprothrombinemia 
 What happens to coagulation when a single clotting factor is elevated?  The answer 
depends on which factor is elevated and its functionality in the clotting cascade.  Previous 
studies by our laboratory painstakingly determined the effect of elevated clotting factors on 
in vitro thrombin generation and fibrin formation28-31, as well as thrombus formation in 
vivo30,31.  For instance, while elevated fibrinogen increased the rate of fibrin formation  
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Figure 1.2.  Arterial thrombosis.  Interplay between abnormalities in blood components, 
the vasculature, and blood flow contribute to the development of arterial thrombosis. Arterial 
thrombosis involves the formation of platelet-rich “white clots” that form after rupture of 
atherosclerotic plaques and exposure of procoagulant material such as lipid-rich macrophages 
(foam cells), collagen, tissue factor, and/or endothelial breach, in a high shear environment. 
Abbreviations: Fgn, fibrinogen; II, prothrombin; IIa, thrombin; TF, tissue factor; TM, 
thrombomodulin.  Figure originally appeared in Wolberg, et al.65  Reprinted with permission 
from Lippincott, Williams, & Wilkins. 
  
 7 
regardless of TF level used to initiate clotting30, elevated factor VIII (FVIII, a cofactor in the 
intrinsic pathway) only increased fibrin formation with low levels of TF31.  Similarly, while 
elevated fibrinogen shortened the time to occlusion (TTO) in a FeCl3 injury model30, 
shortening of the TTO with elevated FVIII was dependent on the extent of injury31. These 
data show how the effects of elevated factors on coagulation kinetics are context-dependent. 
Prothrombin is the inactive zymogen form of thrombin.  Previous studies by our 
laboratory described the in vitro procoagulant effects of elevated prothrombin levels 
(hyperprothrombinemia).  In both purified and plasma-based systems, elevated prothrombin 
increases thrombin generation28,29 and significantly increases fibrin formation and network 
density29.  Interestingly, elevated prothrombin has no effect on platelet activation29, 
suggesting prothrombotic effects of hyperprothrombinemia are due to effects on fibrin 
formation.   
Risk of thrombosis for hyperprothrombinemia patients is vascular bed-specific.  
While there is a clear association between venous thrombosis and elevated prothrombin 
levels32,33, the association is less clear between elevated prothrombin and arterial thrombosis 
risk.34,35  This suggests that vascular bed-specific mechanisms dictate the prothrombotic 
effects of elevated prothrombin.  To investigate the role of elevated prothrombin in vascular 
bed-specific thrombosis, we utilized multiple mouse models of venous and arterial 
thrombosis in a study described in Chapter 2.  Briefly, we determined that acute 
hyperprothrombinemia increases venous thrombosis, but has no detectable effect on arterial 
thrombosis.36  As we found with elevated FVIII, the effects of elevated prothrombin on 
thrombogenesis are context-dependent. 
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Figure 1.3. Venous thrombosis. Interplay among abnormalities in blood components, the 
vasculature, and blood flow contribute to the development of venous thrombosis. Venous 
thrombosis involves the formation of fibrin-rich “red clots” that result from exposure of 
procoagulant activity on intact endothelium plus plasma hypercoagulability, in reduced or 
static blood flow. Venous thrombi are thought to initiate behind valve pockets, in which 
reduced or static flow decreases wall shear stress that normally regulates endothelial cell 
phenotype. Abbreviations: EPCR, endothelial protein C receptor; Fgn, fibrinogen; II, 
prothrombin; IIa, thrombin; RBC, red blood cells; TF, tissue factor; TM, thrombomodulin. 
Figure originally appeared in Wolberg, et al.65  Reprinted with permission from Lippincott, 
Williams, & Wilkins. 
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1.4 Microparticles & Thrombosis 
 Cellular microparticles, also known as microvesicles, are sub-micron plasma 
membrane blebs released from various cell types.  In particular, platelets, monocytes, red 
blood cells, endothelial cells, and tumor cells, have been shown to release microparticles.37-39  
These microparticles circulate in the blood and are primarily of platelet origin in healthy 
individuals.40  However, microparticles of various cellular origins are elevated in diseases 
including CVD41-43, VTE44, and cancer45,46.   
Like their parent cells, microparticles have procoagulant properties that can include 
the presence of TF and/or PS on the outer leaflet of their plasma membrane (Table 1.1).  
While PS exposure appears to be a hallmark of microparticles from all cell types, TF 
expression is restricted to microparticles stemming from TF-expressing parent cells such as 
monocytes and tumor cells.  The presence or absence of TF confers differential procoagulant 
activity on microparticles.  In work detailed in Chapter 3, we show that TF-bearing 
microparticles from monocytes or a monocytic cell line support extrinsic thrombin 
generation and fibrin formation, whereas non-TF-bearing microparticles from platelets 
support intrinsic thrombin generation and fibrin formation.6  This study suggests TF-bearing 
microparticles may be causative for VTE, whereas non-TF-bearing microparticles may only 
contribute to thrombosis after an initiating event. 
Cancer patients, particularly pancreatic cancer patients, with VTE have increased 
microparticle-associated tissue factor activity47, suggesting these cellular blebs may be 
causative for the development of VTE.  To test this concept, we performed a study to 
determine the role of tumor-derived TF in the activation of coagulation and thrombus 
formation in xenograft models of human pancreatic cancer in mice. We found that activation 
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of coagulation only occurred in mice with TF-positive tumors.48    Interestingly, of two TF-
positive pancreatic tumor cell lines that activated coagulation, only one provided detectable 
levels of circulating TF-positive MPs.  These data suggested activation of coagulation was 
due to TF expression by the tumor itself rather than by the MPs. Tumor-bearing mice with 
elevated levels of TF-positive MPs exhibited increased thrombosis in a saphenous vein 
model, while mice injected with TF-bearing microparticles showed increased thrombus 
formation in a concentration-dependent manner in an inferior vena cava stenosis model.48  
These data suggest tumors contribute to activation of coagulation and circulating TF that 
might contribute to thrombosis.   
 
1.5  FXIII & RBCs 
 FXIII is a 320 kDa pro-transglutaminase that circulates in plasma at ~70 nM and 
consists of two catalytic subunits (FXIII-A) and two non-catalytic subunits (FXIII-B) in a 
noncovalent, heterotetramer (FXIII-A2B2).  Essentially all FXIII in plasma circulates in 
complex with fibrinogen49,50, whereas less than 1% of fibrinogen has FXIII bound.  FXIII is 
activated by thrombin51,52 and calcium53-55.  Of note, FXIII activation is accelerated when it is 
bound to fibrinogen56,57 suggesting localization of FXIII on circulating fibrinogen is an 
important factor in its activation.  However, the residues in fibrinogen that mediate 
interaction with FXIII have not been defined.  A study by our group, described in Chapter 4, 
indicates FXIII binds to fibrinogen at the c-terminus of the γ chain and that localization of 
FXIII on fibrinogen is important for normal FXIII activation and fibrin cross-linking.  
Intriguingly, disruption of FXIII binding to fibrinogen causes a defect in retention of RBCs 
within clots (Figure 1.4).  However, the role of RBCs in clots is not fully understood.  
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Figure 1.4. Model of FXIII-dependent RBC retention during clot retraction.  Studies 
described in Chapter 4 examine how delayed or deficient FXIII activity results in reduced 
RBC retention in mouse and human clots. 
 
  
 12 
 The most abundant cell in blood, RBCs are flexible, biconcave, anucleate cells  
derived from bone marrow that circulate at 4-6.x109/mL in humans.  Primary RBC function 
is oxygen transport via its hemoglobin-rich cytoplasm.  RBCs are readily identifiable by most 
macro and microscopic techniques, but are often discarded during blood processing for 
hematological tests.  However, this centrifugal waste may be more important than realized as 
recent studies suggest RBCs are not just passive bystanders, but play an active role in 
coagulation (Table 1.1).   
A growing body of evidence suggests that abnormal RBC quantity and quality 
contribute to clot formation in vivo.  Bleeding times shorten as hematocrit rises in anemic, 
normal, and polycythemic individuals58, and elevated RBC levels are associated with 
increased risk of venous thrombosis in patients with polycythemia vera or patients on 
erythropoietin59,60.  Patients with sickle cell disease (SCD) have abnormal hemoglobin 
polymerization resulting in dysfunctional RBCs with a characteristic “sickled” appearance; 
notably, SCD patients have an increased incidence of large-vessel thrombosis, including 
pulmonary embolism.61  However, an etiologic role for RBCs in VTE remains unclear. 
Once in the clot, RBCs appear to exert direct, complex effects on clot structure and 
stability.  For example, RBCs have been shown to increase the size of pores in the fibrin 
network62, but decrease fibrin network permeability63.  Finally, the presence of RBCs in clots 
suppresses plasmin generation and reduces clot dissolution.64  These observations suggest 
that decreasing thrombus RBC content would accelerate thrombus resolution.  Our recent 
discovery that FXIII activity is required for RBC retention in clots and that FXIII inhibition 
reduces venous thrombus size in mice suggests FXIII may be an attractive target for the 
development of novel anti-thrombotic agents. 
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1.6 Focus of this Dissertation 
The pathophysiologic interplay between plasma clotting factors and blood cells is an 
important research topic to improve our understanding of mechanisms that tip the hemostatic 
balance towards thrombosis in both arterial and venous vascular beds.  The studies comprised 
within this dissertation emphasize the importance of complementary in vitro and in vivo 
studies of coagulation and thrombosis.  We investigated 1) the role of elevated prothrombin 
in arterial and venous thrombosis; 2) the differential procoagulant activities of microparticles 
from different cells; and 3) the role of fibrin(ogen) and FXIII in venous thrombosis. 
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CHAPTER 2:  ELEVATED PROTHROMBIN PROMOTES VENOUS,  
BUT NOT ARTERIAL, THROMBOSIS IN MICE1 
 
 
2.1  Introduction 
 Arterial thrombosis and venous thrombosis/thromboembolism are traditionally 
regarded as distinct diseases with respect to their epidemiology and treatment strategies 
(reviewed in2,3).  The presence of certain non-overlapping risk factors suggests that distinct 
features in the arterial and venous environments confer differential pathophysiology.  Venous 
thrombosis is often associated with acquired or inherited plasma hypercoagulability and is 
thought to be triggered by expression of cell adhesion molecules and procoagulant activity on 
intact endothelium in low shear.  In contrast, arterial thrombosis is typically associated with 
atherosclerotic plaque rupture and exposure of subendothelial cells and highly procoagulant 
material (tissue factor [TF] and collagen) to blood in high shear.  Consequently, venous 
thrombi are high in erythrocyte and fibrin content; whereas, arterial thrombi are platelet-rich.  
Treatment strategies to minimize venous thrombosis/thromboembolism and arterial 
thrombosis (anticoagulants and platelet antagonists, respectively) have reduced efficacy vice 
versa2-4, supporting the premise that unique pathophysiological mechanisms promote 
thrombosis in veins and arteries.    
Individuals with elevated prothrombin (hyperprothrombinemia), including those with 
the G20210A mutation in the prothrombin 3’-untranslated region5,6, have ~3-fold increased 
risk for venous thrombosis.  In particular, the G20210A mutation is associated with ~115-
170% of normal prothrombin activity levels.5-7  This mutation is present in 1-4% of the 
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general European population8, making it the 2nd most common genetic risk factor for venous 
thrombosis in Caucasians.  In contrast, association of either elevated prothrombin or the 
G20210A mutation with arterial thrombosis is unclear.9,10  Although the G20210A mutation 
has been weakly-associated with arterial disease11 including coronary heart disease12, 
ischemic stroke13, and risk of myocardial infarction in young women14 and men15, other 
investigations have failed to support these findings in patients with cerebral ischemia16,17, 
myocardial infarction18, or peripheral arterial events19.  Patient heterogeneity may reconcile 
differences between these studies since arterial risk is increased in patients with additional 
risk factors (e.g., smoking, hypertension, diabetes and/or obesity)14,15; however, the 
independent association between elevated prothrombin and arterial thrombosis is difficult to 
discern in a human cohort and remains unresolved. 
The operant pathological mechanisms of hyperprothrombinemia in either venous or 
arterial vascular beds are also unknown.  Individuals with elevated prothrombin do not have 
increased circulating prothrombin fragment 1.2 levels7, suggesting thrombosis does not result 
from constitutive activation of coagulation.  However, in vitro studies show that following 
coagulation activation, high prothrombin levels increase thrombin generation20-23, induce 
activated protein C resistance24, and promote formation of abnormal fibrin networks20 in 
clots that resist fibrinolysis24,25.  These findings suggest elevated prothrombin levels promote 
thrombosis; however, this effect has never been directly demonstrated in vivo. 
The objectives of the present study were to define the prothrombotic role(s) of 
elevated prothrombin in vivo and distinguish pathologic mechanisms differentiating these 
effects in venous and arterial thrombosis.  We found that elevated prothrombin increased 
plasma thrombin generation ex vivo following TF-dependent initiation of coagulation, but did 
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not activate coagulation or increase baseline thrombin generation in vivo in the absence of 
overt vascular injury.  Following vascular injury, elevated prothrombin increased in vivo 
thrombin generation, but did not increase the rate of platelet accumulation in either arterial or 
venous thrombi.  Elevated prothrombin increased the rate of fibrin deposition and produced 
larger thrombi in models of venous thrombosis.  In contrast, elevated prothrombin did not 
increase the rate of fibrin deposition or shorten the time to occlusion (TTO) in models of 
arterial thrombosis.  These data are the first to show that elevated prothrombin levels directly 
promote venous thrombosis in vivo, and show elevated prothrombin has little to no 
independent contribution to arterial thrombosis in the absence of additional risk factors. 
 
2.2  Materials & Methods 
Proteins and materials.  Human and murine prothrombin and human thrombin were from 
Haematologic Technologies, Inc (Essex Junction, VT).  Murine thrombin was from Enzyme 
Research Laboratories (South Bend, IN).  Human prothrombin was treated with 
inhibitors21,26, concentrated, and dialyzed into sterile 20 mM HEPES (pH 7.4)/150 mM NaCl 
(HBS).  Prothrombin concentrate contained less than 0.004% thrombin (the lower level of 
detection).  Murine thrombomodulin and protein C were from R&D Systems (Minneapolis, 
MN), Pefachrome PCa from Pentapharm (Switzerland), and hirudin from Calbiochem (La 
Jolla, CA).  Rhodamine 6G was from Sigma-Aldrich.  Rabbit polyclonal antibodies against 
human fibrinogen (A0080) and human prothrombin (A0325) were from DAKO (Carpinteria, 
CA).  Fluorescent secondary antibodies and protein labeling kits were from Invitrogen 
(Carlsbad, CA).  Anti-fibrin antibody (59D8) was from a clone generously provided by Drs. 
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Marschall Runge [University of North Carolina (UNC)] and Charles Esmon (Oklahoma 
College of Medicine).  
Murine platelet-poor plasma (PPP) was prepared from blood drawn from the inferior 
vena cava (IVC) of 49 female C57BL/6 mice into 3.2% sodium citrate and processed by 
centrifugation (4,000xg, 20 minutes). 
 
Thrombosis models.  Procedures were approved by the UNC and Medical College of 
Wisconsin Institutional Animal Care and Use Committees.  Mice (6-8 week old male 
C57BL/6) were purchased from Charles River Laboratories (Raleigh, NC) or Harlan 
Laboratories (Indianapolis, IN).  The left saphenous vein or jugular vein was exposed and 
catheterized as described. 27-29  Prothrombin or vehicle (HBS) was administered through the 
catheter on a per weight basis [blood volume (mL) is 7% of body weight (g), plasma is 50% 
of blood volume] 5 minutes before injury.  
The electrolytic injury models were performed as described.30,31  Briefly, mice were 
anesthetized with intraperitoneal pentobarbital, and rhodamine 6G (platelet label), Alexa 
Fluor 647-labeled anti-fibrin (59D8), and prothrombin (to 200%, final) or saline were infused 
via a jugular vein branch 3-5 minutes before thrombus induction.  Antibody 59D8 does not 
inhibit fibrin polymerization.30  Injury was induced with 30-second, 3-V direct current 
application via 140-µm diameter steel blunt-end needle on the carotid artery surface, or with 
a 30-second, 1.5-V direct current application via 70-µm blunt-end needle to the femoral vein 
surface.  Vessels were illuminated with beam-expanded green (532 nm) and red (650 nm) 
laser light.  Fluorescent time-lapse video images were captured over 60 minutes with a low-
light camera attached to a microscope at 100X magnification.  Video images at 2-minute 
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intervals were analyzed for relative fluorophore intensity (ImageJ 1.45s) within the thrombus 
zone and normalized for inter-animal comparisons.  Rates of platelet and fibrin accumulation 
were determined by linear fit to 3 or more points exhibiting the maximal rate of increase. 
The FeCl3/carotid artery thrombosis model was performed as described.28,29  Briefly, 
mice were anesthetized with 1.5-2% isoflurane in oxygen and infused with prothrombin (to 
200%, final) or vehicle (HBS) via left saphenous vein catheter 5 minutes before thrombus 
induction.  The right common carotid artery was dissected and placed on parafilm.  FeCl3 
(7.5%) was applied to the artery for 2 minutes.  The artery was washed with warm saline and 
blood flow was monitored via Doppler transonic flow probe (Indus Instruments, Webster, 
TX).  The TTO was defined as the time between FeCl3 administration and lack of flow for 60 
consecutive seconds. 
The IVC stasis model was performed as described.32,33  Briefly, mice were 
anesthetized with 1.5-2% isoflurane in 2% oxygen and prothrombin (to 300%, final) or 
vehicle was infused via tail vein injection.  Following sterile laparotomy, the intestines were 
exteriorized, the IVC was dissected bluntly, and side branches were ligated with 8-0 Prolene 
suture and lumbar branches closed by cautery. The IVC was separated from the aorta by 
blunt dissection and completely ligated with 8-0 Prolene suture.  After replacing the 
intestines, the muscle layer was closed with 5-0 vicryl suture and skin closed with 8-0 
Prolene suture and skin glue.  Mice recovered with analgesia (buprenorphine, 0.05 mg/kg 
subcutaneous).  After 12 hours, blood was drawn from the IVC above the ligation site into 
3.2% sodium citrate and processed to PPP by centrifugation at 5,000xg for 10 minutes.  
Thrombi were collected and weighed. 
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Detection of circulating human prothrombin antigen.  PPP (1:10 dilution) was separated on 
Novex 10% Tris-Glycine gels and transferred to polyvinylidene difluoride membranes 
(Invitrogen).  Membranes were blocked for 1 hour at room temperature with Odyssey 
blocking buffer (LI-COR Biosciences, Lincoln, NE).  Primary antibodies were incubated 
overnight at 4°C.  After washing three times with 10 mM phosphate (pH 7.4), 150 mM NaCl 
containing 0.1% Tween-20, membranes were incubated with fluorescently-labeled secondary 
antibodies (1:15,000 dilution) for 1 hour at room temperature.  Membranes were then washed 
3 times and scanned using an Odyssey® Infrared Imaging System (LI-COR Biosciences).  
Band intensity was quantified by densitometry. 
 
Detection of circulating human prothrombin activity.  The final level of circulating 
prothrombin was confirmed by clotting assay in separate, uninjured mice as described.29  
Briefly, blood was drawn from the IVC 5 minutes after infusion into 3.2% sodium citrate and 
processed to PPP by centrifugation (5,000xg, 10 minutes).  Murine PPP was mixed with 
human prothrombin-deficient PPP (5% murine PPP, 95% prothrombin-deficient PPP), and 
clotting was initiated with Kontact aPTT reagent (40%, final) and calcium chloride (10 mM, 
final).  Clot formation was followed in a SpectraMax Plus 340 plate reader (Molecular 
Devices, Sunnyvale, CA)34 and compared to a standard curve.   The prothrombin level of 
mice infused to 300% prothrombin (final, endogenous murine plus infused human) was as 
expected (323±12% of normal activity, n=2). 
 
Calibrated automated thrombography.  Blood was drawn from the IVC into 3.2% sodium 
citrate and processed to PPP by centrifugation (5,000xg, 10 minutes).  Thrombin generation 
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was measured as described.35 Briefly, murine PPP (10 µL) was added to 30 µL HBS, and 10 
µL of PPP Reagent Low or Calibrator Reagent.  After 10 minutes at 37 °C, reactions were 
initiated by addition of 10 µL fluorogenic substrate/CaCl2.  Thrombin generation was 
detected on a Fluoroskan Ascent fluorometer (Thermo Labsystems) and evaluated using 
Thrombinoscope software v3.0.0.29. 
 
Measurement of circulating thrombin-antithrombin (TAT) complexes.  TAT levels were 
measured by ELISA (Enzygnost TAT microELISA, Siemens Healthcare Diagnostics Inc., 
Deerfield, IL) using citrated PPP prepared from IVC blood draws.  This kit detects mouse 
antithrombin in complex with either mouse or human thrombin, but is slightly (1.3-fold) 
more sensitive to human/mouse chimeric TAT complexes than mouse/mouse TAT 
complexes (data not shown). 
 
Statistical Methods.  Descriptive statistics (mean and standard deviation [SD] or standard 
error of the mean [SEM], as indicated) were calculated for each experiment.  Analysis of 
variance (ANOVA) was used to identify significance in experiments with more than two 
dosing groups, with posthoc Student-Newman-Keuls tests for between-groups comparisons.  
Datasets with only two comparison groups (control and elevated prothrombin) were 
compared using a Student t test (normally-distributed data) or Wilcoxon-Mann-Whitney 
Rank Sum Test (non-normally distributed data) in Kaleidagraph version 4.1.3.  P<0.05 was 
considered statistically significant. 
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Figure 2.1. Human prothrombin supports thrombin generation in murine plasma and 
mouse thrombomodulin reduces thrombin generation in mouse plasma spiked with 
human prothrombin.  Thrombin generation was measured in the absence and presence of 
200 nM thrombomodulin in A) murine PPP spiked with vehicle, B) murine PPP spiked to 
200% with murine prothrombin, and C) murine PPP spiked to 200% with human 
prothrombin. 
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2.3  Results 
Human prothrombin is active in murine plasma.  The in vivo hyperprothrombinemia model 
was developed by infusing mice with human prothrombin.  Human prothrombin and the 
thrombin B chain have 81.4% and 88.8% amino acid identity with murine prothrombin and 
thrombin, respectively, and highly-conserved substitutions in non-identical residues.36  
Human and mouse thrombin bind and cleave human and mouse fibrinogen37, activate 
platelets to form aggregates with pseudopodia38, bind murine thrombomodulin, and support 
activated protein C generation39,40.  To assess the ability of human (pro)thrombin to support 
thrombin generation in murine plasma, murine plasma was spiked with vehicle or murine or 
human prothrombin to 200% (final, endogenous plus spiked human prothrombin) and 
thrombin generation was measured by calibrated automated thrombography in the absence 
and presence of 200 nM murine thrombomodulin.  Thrombin generation peaks were 
49.4±7.2, 82.4±13.8 and 90.4±5.2 nM (mean±SD, n=2-3) for plasma plus vehicle, plasma 
plus murine prothrombin, or plasma plus human prothrombin, respectively, and addition of 
murine thrombomodulin reduced the thrombin peaks by 73, 74, and 64%, respectively 
(Figure 2.1).  These data demonstrate that human (pro)thrombin is compatible with the 
murine procoagulant and anticoagulant systems.  
 
In the absence of vessel injury, elevated prothrombin does not activate coagulation.  Platelet-
poor plasma (PPP) from patients with elevated prothrombin demonstrates increased thrombin 
generation ex vivo7,23; however, these patients do not have higher circulating prothrombin 
fragment 1.2 compared to age-matched controls.7  We hypothesized that elevated 
prothrombin does not independently cause thrombin generation in the absence of vascular  
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Figure 2.2. Human prothrombin circulates in mice 12 hours post-infusion.  Twelve 
hours after infusion, blood was drawn from the IVC into 3.2% sodium citrate and processed 
to PPP.  PPP samples were separated by 4-12% SDS-PAGE, transferred to PVDF 
membranes, and probed with rabbit polyclonal anti-human prothrombin antibody.  Band 
intensity was quantified by densitometry.  Since human prothrombin is better detected by the 
rabbit polyclonal antibody, the blot readily indicates the presence of human prothrombin in 
these samples. 
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injury, but increases thrombin generation following TF exposure.  To test this hypothesis, we 
infused prothrombin (to 300% of normal levels; total prothrombin equals endogenous murine 
prothrombin plus infused human prothrombin) or vehicle [20 mM HEPES (pH 7.4)/150 mM 
NaCl (HBS), Control] into uninjured mice and measured prothrombin antigen by western 
blotting, thrombin generation ex vivo by calibrated automated thrombography, and thrombin-
antithrombin complex (TAT) levels by ELISA 12 hours after infusion.  Human prothrombin 
still circulated in mice 12 hours post-infusion and was strongly detected by the rabbit anti-
human prothrombin antibody (Figure 2.2).  Consistent with humans, thrombin generation 
was significantly elevated in PPP from prothrombin-infused mice compared to controls 
(49.5±2.1 versus 39.3±2.5 peak thrombin, respectively, mean±SEM, P<0.04) (Figure 2.3A) 
following initiation of coagulation ex vivo.  However, also consistent with that seen in 
humans, circulating TAT levels in mice with elevated prothrombin, even at this high level, 
were not elevated compared to controls (2.4±1.4 versus 3.8±4.0 ng/mL, respectively, 
mean±SEM, P=0.26) (Figure 2.3B).  These data reconcile outwardly discordant findings 
regarding thrombin generation in hyperprothrombinemic individuals measured ex vivo and in 
vitro by showing that elevated prothrombin does not increase baseline hemostatic “idling” in 
the absence of vascular injury, but augments thrombin generation following a procoagulant 
trigger. 
 
Elevated prothrombin accelerates fibrin deposition and produces larger thrombi in venous 
thrombosis models.  To characterize the effect of elevated prothrombin on venous thrombosis 
in vivo, we first triggered thrombosis in the murine femoral vein via electrolytic injury and 
used intravital fluorescence detection to characterize the temporal and spatial contributions of  
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Figure 2.3.  In the absence of vessel injury, elevated prothrombin does not activate 
coagulation.  HBS (Control) or human prothrombin was infused into mice via tail vein 
injection to 300%, final (mouse plus human).  Twelve hours after infusion, blood was drawn 
from the IVC into 3.2% sodium citrate and processed to PPP.  A) PPP from mice infused 
with prothrombin (to 300%) or HBS (Control) was diluted 1:3 and coagulation was triggered 
by addition of TF/lipid.  Thrombin generation was measured by calibrated automated 
thrombography (n=3/group).  B) TAT levels were measured by ELISA (n=5/group).  Bars 
show mean±SEM. 
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elevated prothrombin to thrombus formation.  The electrolytic injury model induces mural 
thrombus formation via iron-mediated injury that causes early platelet accumulation followed 
by fibrin accumulation30 (Figure 2.4A, Supplemental Videos I and II, available online1).  
Thrombus formation in this model is reduced by heparin, consistent with the sensitivity of 
venous thrombosis to thrombin generation.41  We tested 2 levels of prothrombin:  130% and 
200% (final); these levels were chosen to approximate the mean and upper end of the 
pathophysiologic range.  Neither prothrombin concentration significantly increased the rate 
or total amount of platelet accumulation in femoral vein thrombi (Figures 2.4B, D).  
However, the plasma prothrombin level showed a dose-dependent effect on fibrin 
accumulation in the vein.  At 60 minutes, fibrin accumulation in mice infused to 130% and 
200% prothrombin was 1.7- (P<0.06) and 3.5- (P<0.002) fold higher, respectively, than 
control mice (Figure 2.4C), and mice infused with 200% prothrombin exhibited a 
significantly (2.3-fold, P=0.006) increased fibrin accumulation rate than control mice (Figure 
2.4D).  Furthermore, in contrast to control thrombi that remained relatively localized to the 
thrombus induction site, thrombi in prothrombin-infused mice showed considerable 
downstream elongation of a mass containing both fibrin and platelets (Supplemental Videos I, 
II). 
We also characterized the effect of elevated prothrombin on venous thrombosis in an 
inferior vena cava (IVC) ligation (stasis) model that triggers venous thrombosis via vessel 
distention, blood stasis, and dysfunction (exposure of vessel wall TF) of intact endothelium.42  
For both control and prothrombin-infused mice, circulating TATs were significantly higher 
in mice that underwent IVC ligation than in mice that did not (Figure 2.5A), demonstrating 
activation of coagulation following vessel ligation.  Circulating prothrombin was spiked to  
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Figure 2.4. Elevated prothrombin increases the rate and extent of fibrin deposition 
following electrolytic injury to the femoral vein.  Mice were infused with vehicle (control) 
or prothrombin to 200% of normal.  Thrombosis was induced by electrolytic injury as 
described in Methods.  A) Representative images of platelet and fibrin accumulation 60 
minutes after induction of femoral vein thrombosis via application of electric current are 
shown.  Flow is from left to right; field dimensions are 3.20 x 0.85 mm (width x height).  B-
C) Relative fluorescence intensity of platelet (B) and fibrin (C) accumulation following 
electrolytic injury to the femoral vein (mean±SEM, n=8/group, *P<0.002).  Symbols are:  
control (open circles) and prothrombin-infused (closed triangles, 130%; closed circles, 
200%).  D) Maximum rate of platelet and fibrin accumulation during femoral vein thrombus 
formation following electrolytic injury (mean±SEM, n=8/group). 
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300% so that levels remained elevated for the duration of thrombus formation (12 hours).  
Following IVC ligation, TATs were more than 2-fold higher in prothrombin-infused mice 
compared to control mice (47.9±6.5 versus 21.2±4.5 ng/mL, respectively, mean±SEM, 
P<0.009, Figure 2.5A), suggesting elevated prothrombin augmented thrombin generation 
during venous thrombogenesis.  Following IVC ligation, all prothrombin-infused and control 
mice developed thrombi within 12 hours.  Similar to that seen in the electrolytic injury model, 
thrombi in prothrombin-infused mice were significantly larger than thrombi in control mice 
[27.6 (26.1-43.6) versus 22.6 (9.5-27.7) mg, respectively, median (range), P=0.01, Figure 
2.5B], and in some mice extended into the iliac branches.  Together, these data show that 
elevated prothrombin augments venous thrombus formation in vivo by increasing thrombin 
generation and intravascular fibrin deposition.  
 
Elevated prothrombin has little to no effect on the TTO or rate of platelet accumulation in 
arterial thrombosis models.  We then used the electrolytic injury and real-time fluorescence 
detection method to measure the kinetics of platelet and fibrin accumulation in control and 
prothrombin-infused mice during arterial thrombosis (Figures 2.6A-D, Supplemental Videos 
III and IV, available online1).  Platelet accumulation in the artery was 3.2-fold faster 
(P<0.003) than that in the vein (Figure 2.6B, D versus 2.4B, D) and was complete within 10 
minutes, consistent with the strongly platelet-dependent mechanism associated with arterial 
thrombosis.  At 60 minutes, arterial thrombi also had 50% less fibrin deposition than venous 
thrombi (Figure 2.6C versus 2.4C), further illustrating mechanistic differences in thrombus 
formation in these two vessels.  Arterial clots exhibited some embolization, indicated by the 
loss of mean fluorescence.  As in the venous model, prothrombin levels were raised to 130  
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Figure 2.5.  Elevated prothrombin produces larger venous thrombi by increasing 
thrombin generation following IVC ligation.  A) IVC stasis was induced in mice infused 
with prothrombin (to 300%) or vehicle control.  Twelve hours after ligation, blood was 
collected into citrate from just above the ligation site.  TAT levels were measured from 
ligated (n=6-8/group) and uninjured mice (n=5/group) in parallel. Bars show mean±SEM.  B) 
Twelve hours after ligation, the IVCs plus thrombi were excised and weighed.  The box plot 
indicates medians and upper and lower quartiles (n=6-8/group).   
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and 200% of normal (final).  Neither prothrombin concentration significantly increased either 
the rate or total amount of platelet accumulation, or the rate of fibrin accumulation in carotid 
artery thrombi (Figures 2.6B-D).  Elevated prothrombin increased fibrin deposition at 60 
minutes (~2-fold, Figure 2.6C), but this difference did not reach statistical significance 
(P<0.085). 
We then tested the effect of elevated prothrombin in a second model of arterial 
thrombosis.  The FeCl3 application/carotid artery model triggers arterial thrombosis via 
generation of reactive oxygen species and exposure of collagen, resulting in a platelet-rich 
thrombus.43-45  Since neither prothrombin concentration significantly altered arterial 
thrombus formation in the electrolytic model, we only tested the higher concentration of 
prothrombin (infusing to 200%, final) in the FeCl3/carotid artery model.  Prothrombin 
infusion transiently elevated TAT levels (12.6±3.2 ng/mL), likely reflecting trace (<0.004%) 
thrombin contamination in the prothrombin concentrate that was immediately inhibited by 
endogenous antithrombin (present in 1000-fold excess, 2.5 µM plasma level) with no 
physiologic effects (data not shown and 46,47).  For both control and prothrombin-infused 
mice, circulating TATs were significantly higher in mice that underwent FeCl3 injury than in 
mice that did not (Figure 2.6E), demonstrating activation of coagulation following FeCl3 
injury.  Following FeCl3 injury, TAT levels were significantly different between control and 
prothrombin-infused mice (13.9±1.7 versus 23.5±2.6, for control and prothrombin-infused 
mice, respectively, P<0.007, Figure 2.6E).  Interestingly, the absolute increase in TAT levels 
following arterial injury was similar in both control and prothrombin-infused mice, 
suggesting arterial injury activated coagulation to a similar degree in both groups.  Consistent 
with this observation, both control and prothrombin-infused mice developed stable, occlusive  
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Figure 2.6.  Elevated prothrombin does not increase thrombin generation or the rate of 
platelet or fibrin accumulation, and does not shorten the TTO in arterial injury models.  
A) Mice were infused with vehicle (Control) or prothrombin to 130 or 200% of normal.  
Thrombosis was induced by electrolytic injury as described in Methods.  Representative 
images of platelet and fibrin accumulation 60 minutes after induction of carotid artery 
thrombosis via electrolytic injury are shown.  Flow is from left to right; field dimensions are 
3.20 x 0.85 mm (width x height).  B-D) Relative fluorescence intensity of platelet (B) and 
fibrin (C) accumulation following electrolytic injury to the carotid artery (mean±SEM, n=7-
8/group).  Symbols are:  control (open circles) and prothrombin-infused (closed triangles, 
130%; closed circles, 200%).  D) Maximum rate of platelet and fibrin accumulation during 
carotid artery thrombosis following electrolytic injury (mean±SEM, n=7-8/group).  E) Mice 
were infused with vehicle (Control) or prothrombin to 200% of normal.  Thrombosis was 
induced by 7.5% FeCl3 application to the carotid artery for 2 minutes.  Following thrombus 
formation, blood was collected from the IVC into citrate and processed to PPP.  TAT levels 
were measured in FeCl3-treated (n=7-10/group) and uninjured mice (n=4/group) in parallel.  
Bars show mean±SEM.  F) Following FeCl3 injury, the TTO was determined by flow probe.  
The box plot indicates medians and upper and lower quartiles (n=10/group); the open circle 
indicates one mouse that did not occlude.   
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thrombi, and the time to vessel occlusion in prothrombin-infused mice was not different from 
controls (9.5 [4.3-40.0] versus 6.4 [4.5-8.5] minutes, respectively, median [range], Figure 
2.6F).  Thus, elevated prothrombin did not significantly increase platelet or fibrin 
accumulation during arterial thrombus formation or shorten the time to artery occlusion.  
Together, these data show that although elevated prothrombin promotes venous thrombus 
formation, it does not significantly augment arterial (platelet-dependent) thrombosis. 
 
2.4  Discussion 
Elevated prothrombin is a well-established risk factor for venous thrombosis, but its 
relationship to arterial thrombosis is unclear.  Using state-of-the-art in vivo models of venous 
thrombosis and arterial thrombosis, we show that elevated prothrombin did not increase 
baseline prothrombotic markers in unchallenged mice, but did increase thrombin generation 
following venous injury.  The presence of elevated prothrombin did not accelerate 
intravascular platelet accumulation following either venous or arterial injury.   In venous 
thrombosis models, mice with elevated prothrombin exhibited an increased rate and amount 
of fibrin accumulation, thrombus extension and formation of thrombi with increased mass.  
However, in arterial thrombosis models, elevated prothrombin slightly (non-significantly) 
increased the total amount of fibrin deposited, but did not increase the rate of fibrin 
accumulation or shorten the TTO.  These findings suggest elevated prothrombin has little to 
no independent contribution to arterial thrombosis, and are the first to show that elevated 
prothrombin levels directly promote venous thrombosis in vivo. 
The choice of murine thrombosis model for investigating human thrombosis has been 
the subject of considerable debate because many models fail to recapitulate key aspects of the 
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arterial and venous thrombogenic processes.48  An important strength of our study was the 
use of complementary arterial and venous models to delineate both kinetic processes and 
their consequences for thrombus composition.  Complementary, integrated information from 
the two arterial models and two venous models reveals both common and vascular bed-
specific processes operant in these vessels that are consistent with the histological appearance 
of arterial and venous thrombi isolated from humans.  Arterial injury produced rapid platelet 
accumulation; whereas, venous injury resulted in slower thrombus formation with fibrin 
accumulation.  We used models that produced both occlusive (FeCl3/carotid and IVC) and 
non-occlusive (electrolytic injury) thrombi.  Findings were consistent within vessels, but 
differed between arteries and veins, suggesting these models are sensitive to the unique 
physical and biochemical environments within the different vessels. 
We detected both common and vascular bed-specific effects of elevated prothrombin 
on arterial and venous thrombosis.  Elevated prothrombin significantly augmented 
endogenous thrombin generation in the venous model, but only slightly (non-significantly) in 
the arterial model (Figures 2.5A, 2.6E).  Consistent with our findings, a recent study showed 
that ApoE-/- mice expressing half of the prothrombin level of wild type mice (FII-/+) are not 
protected from arterial thrombosis, supporting the conclusion that variation in the 
prothrombin level does not mediate arterial occlusion times.49  Notably, although thrombin is 
a potent agonist for platelet activation, elevated prothrombin did not accelerate the rate of 
platelet accumulation in either arteries or veins (Figures 2.4D, 2.6D).  These findings are 
consistent with our prior observation that 5% prothrombin is both necessary and sufficient to 
maximize platelet activation.20  Consequently, elevated prothrombin did not accelerate 
arterial occlusion, a platelet-dominated process.  In contrast, the increased thrombin 
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generation significantly increased fibrin deposition and therefore, venous thrombosis, a 
fibrin-dominated process.  We previously showed that elevated prothrombin also promotes 
the thrombin concentration-dependent formation of plasma clots with an abnormally dense 
fibrin network.20  Although fibrin network structure is difficult to assess in thrombi in the 
presence of cells, combined, these results suggest that in veins, elevated prothrombin 
promotes thrombi with fibrin networks that have both increased mass and increased network 
density.  Both properties are associated with increased clot stability in vitro and in vivo, and 
have been correlated with increased thrombosis risk.50 
It is interesting that while elevated prothrombin did not accelerate arterial occlusion 
after FeCl3 injury, elevated plasma factor VIII does51-53.  Both elevated prothrombin and 
elevated factor VIII increase thrombin generation in vitro20-22,53,54 and in vivo (Figure A and 
51).  However, elevated factor VIII significantly shortens the lag time to platelet aggregation 
in vitro51 and trends towards increased platelet accumulation in vivo53; whereas, elevated 
prothrombin did not significantly change the rate of platelet aggregation in vitro20 or in vivo 
(Figures 2.4D, 2.6D).  These data suggest elevated factor VIII modulates an early 
(amplification) phase of coagulation when thrombin levels are relatively low and platelet 
activation is taking place.  Consequently, platelet-dependent arterial thrombosis models are 
sensitive to the effects of elevated factor VIII, but not to elevated prothrombin.  This 
observation is consistent with the premise that procoagulant factors have complementary, but 
distinct, roles in different phases of coagulation.55 
Previous studies on the association between elevated prothrombin and arterial 
thrombosis (myocardial infarction or ischemic stroke) have been inconsistent, showing either 
no or a modest relationship.9-19  One explanation for these differences is that risk is present 
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only in specific groups.  Of interest are observations that relative risk increases when another 
identifiable cardiovascular risk factor is also present and appears higher than from either risk 
factor alone, suggesting an additive or synergistic interaction.14,15  A strength of our murine 
model in which prothrombin levels were acutely elevated in healthy wild type mice is the 
clear absence of other risk factors.  Nonetheless, the co-existence of additional known or 
unidentified risk factors may augment the positive associations detected in prior studies with 
human cohorts.  For example, on an atherosclerosis-prone background (ApoE-/-), chronic 
plasma hypercoagulability (TMPro/Pro) increases atherogenesis and plaque formation, both of 
which are associated with atherothrombosis, and reduced prothrombin levels attenuate 
atherosclerotic lesion formation.49 
This study has potential limitations.  First, we used human prothrombin to increase 
circulating levels in the mouse.  However, published studies36-40 as well as our data show 
human prothrombin is stable in murine circulation and participates in murine pro- and anti-
coagulant pathways.  Moreover, the infusion strategy enabled us to precisely control the level 
of circulating prothrombin.  Second, the infusion model used in these experiments does not 
reflect pathologic effects that chronic exposure to elevated prothrombin could have on the 
vasculature.  Atherosclerotic disease reflects chronic vascular injury with occurrences of 
acute injury (plaque disruption and TF exposure).  However, a major strength of the infusion 
model is that it enabled us to isolate and investigate the immediate, direct effects of elevated 
prothrombin on thrombus formation.  These data on acute effects will be critical for 
interpreting findings from mice with genetically-induced chronic plasma hypercoagulability 
(e.g., factor V Leiden mice); comparison of short-term and long-term exposure to 
hypercoagulability is likely to reveal interesting mechanisms that predispose these 
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individuals to thrombosis.  Third, the thrombosis models we used differed in methodologic 
aspects, including anesthesia and analgesia protocols.  However, the observation that 
elevated prothrombin exhibited consistent effects in each of the venous and each of the 
arterial models suggests the observed effects were not due to the methodologies, but to the 
prothrombin level, itself. Finally, the arterial and venous models used in this study were 
sensitive to thrombus formation, but did not reflect additional effects elevated prothrombin 
may have on thrombus stability.  For example, although groups have demonstrated increased 
activation of the thrombin activatable fibrinolysis inhibitor in plasma with increased 
prothrombin, we did not evaluate the long-term resistance of thrombi to fibrinolysis.  
In summary, our findings demonstrate that elevated prothrombin does not trigger 
endogenous thrombin generation in the absence of vascular injury, suggesting that in lieu of a 
signal that initiates coagulation, plasma hypercoagulability is not independently 
prothrombotic.  These data suggest that increased coagulation biomarkers (e.g., fragment 1.2 
or TATs) indicate vascular dysfunction that, when coupled to additional plasma 
prothrombotic potential, promote thrombosis.  Our findings further show that elevated 
prothrombin increases thrombin generation following vascular injury.  Elevated prothrombin 
does not accelerate platelet activation in either the artery or the vein, but significantly 
increases the rate and amount of fibrin deposition following venous injury.  These findings 
are consistent with findings that elevated prothrombin is associated with venous thrombosis 
in humans5-7,56, but is only weakly associated with arterial thrombosis in the absence of other 
risk factors.14-19,56  These results support the relevance of murine thrombosis models to  
 
 
 42 
studies of hypercoagulability-related thrombosis in humans.  Integrating complementary in 
vivo models is a powerful approach to investigate the underlying mechanisms of hemostatic 
and thrombotic processes. 
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CHAPTER 3:  DIFFERENTIAL CONTRIBUTIONS OF MONOCYTE- AND 
PLATELET-DERIVED MICROPARTICLES TOWARDS THROMBIN 
GENERATION AND FIBRIN FORMATION AND STABILITY1 
 
 
3.1  Introduction 
Once considered simply cell debris, microparticles (MPs) are bioactive sub-micron 
(0.1-1 µm) membrane vesicles shed from activated and apoptotic cells in culture and in vivo.  
While detectable in healthy controls2, MP levels are greatly elevated in patients with diseases 
including venous thromboembolism3, hypertension4, diabetes mellitus5, and cancer6,7.  
Platelet-derived MPs (PMPs) comprise the largest fraction of MPs in healthy controls2 and 
patients6,8.  PMP concentrations in patients range from ~3000-11,000/µL.3,5,9  Monocyte-
derived MPs (M-MPs) are low or undetectable in healthy controls, but circulate at levels 
from ~300-1300/µL in sickle cell disease, cancer, and other diseases.3,5,7,10  
 Despite studies demonstrating circulating MPs in healthy individuals and patients, 
MP-mediated mechanisms contributing to hemostasis or thrombosis are not understood.  MPs 
bear surface antigens from their parent cells and anionic phospholipids such as 
phosphatidylserine (PS).11  These properties are thought to define MP function.  Observations 
that MPs support thrombin generation2,12 suggest MPs contribute to hemostasis via “idling” 
of the coagulation system, evidenced by the presence of activation peptides and prothrombin 
fragment 1.2 in healthy individuals13.  However, it is difficult to confirm the role of MP 
procoagulant activity in hemostasis in vivo because MPs cannot be depleted from circulation.  
Increased levels of MPs in thrombotic disease suggest MP procoagulant activity tips 
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coagulation “idling” towards full-fledged activation and promotes thrombosis.  TF-bearing 
MPs, in particular, may independently initiate or propagate coagulation via recruitment to 
developing thrombi.14-16  Human M-MPs promote fibrin accumulation in a murine carotid 
artery ligation model17, and injection of MPs isolated from mice after inferior vena cava 
thrombosis into new mice prior to inferior vena cava ligation increases thrombus weight at 
early time points.18  The mechanism(s) by which MP procoagulant activity increases fibrin 
deposition, thrombus growth, and/or weight are not known.   
 Thrombin generation promotes clotting and clot stability by modulating fibrin 
properties, including its network structure and resistance to fibrinolysis.19,20  These studies 
suggest MP procoagulant activity directly increases fibrin formation and stability.  However, 
although procoagulant activity of heterogeneous MP pools isolated from plasma has been 
examined, to our knowledge, no study has examined how MPs from different parent cells 
promote procoagulant activity or fibrin production or quality.  This information gap limits 
clinical interpretation of MP function in healthy individuals or pathologic contributions of 
elevated levels of certain MP subtypes in patients.  
The goal of this study was to determine the specific contributions of monocyte- and 
platelet-derived MPs to thrombin generation and fibrin formation, structure, and stability.  
We prepared MPs from isolated human platelets, monocytes, and a monocytic cell line 
(THP-1) and compared their physical and biochemical properties.  Our data show monocyte-
derived MPs initiate thrombin generation and fibrin formation via their TF activity, whereas 
platelet-derived MPs propagate thrombin and fibrin production in TF- or contact-triggered 
plasma.  These findings suggest MPs from different parent cells uniquely contribute to 
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coagulation, and that the relative concentration of circulating MPs from different cell types 
influences thrombosis risk. 
 
3.2  Materials & Methods 
Materials.  Monocyte Negative and Positive Selection Kits were from Miltenyi BioTec 
(Auburn, CA).  Accu-Prep lymphocyte gradient medium was from Accurate Chemical Co. 
(Westbury, NY).  Prostacyclin I2 was from Cayman Chemical Co. (Ann Arbor, MI).  
Thrombin receptor agonist peptide (TRAP) was from Bachem Inc. (Torrence, CA).  
Convulxin was from Centerchem Inc. (Norwalk, CT).  Calcium Ionophore (A23187), 
lipopolysaccharide (LPS), control IgG (MOPC-1), and bovine serum albumin (BSA) were 
from Sigma Aldrich Corp. (St. Louis, MO).  Fluorescein isothiocyanate (FITC)-Annexin V 
antibody and Annexin V Binding Buffer were from Beckman Coulter (Brea, CA).  
Phycoerythrin-anti-CD41 antibody and Megamix beads were from BioCytex (Marseille, 
France).  Allophycocyanin (APC)-anti-CD14 antibody was from R&D Systems 
(Minneapolis, MN).  Innovin was from Siemens Healthcare Diagnostics (Deerfield, IL).  
Mouse anti-human TF antibody (HTF-1, “anti-TF”)21 was provided by Dr. Ronald Bach 
(Minneapolis VA Medical Center, MN), and recombinant factor VIIa by Novo Nordisk 
(Denmark).  Human factor X was from Enzyme Research Laboratories (South Bend, IN).  
Human factors Xa, Va, prothrombin, and corn trypsin inhibitor (CTI) were from 
Haematologic Technologies, Inc. (Essex Junction, VT).  Thrombin fluorogenic substrate (Z-
Gly-Gly-Arg-AMC) and calibrator (α2-macroglobulin/thrombin) were from Diagnostica 
Stago (Parsippany, NJ).  Tissue plasminogen activator (tPA) was from Calbiochem (La Jolla, 
CA).  Citrated, contact-inhibited (18.6 µg/mL CTI22), normal-pooled, platelet-free plasma19 
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was prepared from 27 individuals, with final centrifugation (20,000xg, 20 minutes) to 
prepare MP-depleted plasma (MDP). 
 
Primary cell isolation.  Peripheral blood mononuclear cells (PBMCs), monocytes, and 
platelets were freshly-isolated from whole blood from healthy donors in a protocol approved 
by the University of North Carolina (UNC) Institutional Review Board.  Blood was collected 
into 3.2% sodium citrate and centrifuged (150xg, 20 minutes).  The platelet-rich plasma was 
treated with 50 ng/mL prostacyclin I2 to prevent nonspecific activation of platelets during 
preparation and centrifuged (400xg, 20 minutes) to pellet platelets.  Platelets were re-
suspended in warm (37 °C) Tyrode’s buffer [1.5 mM N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid, 0.33 mM NaH2PO4 (pH 7.4), 13.8 mM NaCl, 0.27 mM KCl, 0.1 mM 
MgCl2, 0.55 mM dextrose, 1 mg/mL BSA] with 50 ng/mL prostacyclin I2 and incubated for 
30 minutes at 37 °C before stimulation.  To isolate PBMCs and monocytes, the buffy coat 
and erythrocytes were diluted with Hank’s balanced salt solution containing 5 mM 
ethylenediamine tetraacetic acid (HBSS/EDTA), layered over Accu-prep Lymphocyte 
gradient medium, and centrifuged (400xg, 30 minutes).  The PBMC buffy coat fraction was 
removed, washed twice by centrifugation at 250xg, and re-suspended in HBSS/EDTA.  For 
negative and positive monocyte selection, the PBMC buffy coat was washed twice and re-
suspended in ice-cold MACS sorting buffer (phosphate-buffered saline/0.5% BSA/2 mM 
EDTA).  Negative and positive monocyte selection kits were used according to the 
manufacturer’s instructions.  Final enriched monocyte populations were suspended in 
Macrophage-Serum-Free Media (Gibco, Grand Island, NY).     
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Cell culture.  Human monocytic leukemia cell line (THP-1) was obtained from Dr. Nigel 
Mackman (UNC), and cultured in RPMI 1640 media with 10% fetal bovine serum. 
 
Microparticle isolation.  Platelets were stimulated for 30 minutes at room temperature with 6 
or 50 µg/mL TRAP, 6 or 50 µg/mL TRAP plus 500 ng/mL convulxin (TRAP/convulxin), or 
10 µM Ca2+ ionophore (A23187).  There were no differences in peak thrombin generation 
between PMPs generated with 6 or 50 µg/mL TRAP.  Samples were centrifuged (1,500xg, 15 
minutes) and MP-containing supernatants were collected.  PBMCs, monocytes, and THP-1 
cells were stimulated with 100 ng/mL LPS (6 hours, 37 °C) in Macrophage Serum-Free 
Media; this condition supports cell stimulation in the absence of LPS-binding protein.23  
Trypan blue (HyClone, Logan, UT) exclusion experiments indicated less than 10% of 
monocytes and less than 15% of THP-1 cells were dead following the 6-hour incubation.  
Cells were removed by sequential centrifugation (500xg for 10 minutes, 1,500xg for 15 
minutes, 13,000xg for 2 minutes).  MPs were pelleted (20,000xg, 15 minutes), re-suspended 
in HEPES-buffered saline with 0.1% BSA (HBS/BSA), and re-pelleted (20,000xg, 15 
minutes).  MP pellets were re-suspended in HBS/BSA and stored at 4 °C up to one week.  
Control experiments showed no difference in thrombin generation in fresh and 1 week-old 
MPs (9.6±2.7 versus 12.0±0.9 nM peak thrombin, respectively). 
 
Microparticle enumeration.  Flow cytometry of washed MPs was performed on an LSR-II 
flow cytometer (BD Biosciences, San Jose, CA), using Megamix polystyrene beads (0.5, 0.9, 
and 3 µm) to gate the MP region by forward- and side-scatter.24  MPs were incubated with 
antibodies in Annexin V Binding Buffer.  FITC-Annexin V was used to detect PS.  
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Phycoerythrin-anti-CD41 was used as a cell marker for PMPs and APC-anti-CD14 as a 
marker for PBMC-MPs and M-MPs.  Fluorospheres (10 µm) were added and samples were 
analyzed for PS-positive/cell marker-positive (dual positive) events.  MP concentration was 
determined per: [(Dual positive Events/Fluorosphere Bead Events)* Fluorosphere Bead 
Concentration]*Dilution Factor. 
 
Microparticle physical characterization.  Transmission electron microscopy (TEM) was 
performed by depositing MPs onto carbon-coated Formvar copper grids treated with 0.01% 
poly-L-lysine.  MPs were negatively stained with 3% ammonium molybdate (pH 7.0)/0.1% 
trehalose and imaged on a LEO EM910 transmission electron microscope (Carl Zeiss SMT, 
Peabody, MA) operating at 80 kV.  Digital images were recorded using a Gatan Orius CCD 
Digital Camera and Digital Micrograph 3.11.0 (Gatan INC, Pleasanton, CA).  MP diameters 
were measured using Adobe Photoshop 8.0.    
Nanoparticle Tracking Analysis (NTA) was performed using the Nanosight NS500 
system (NanoSight, Amesbury, UK), which focuses a laser beam through a suspension of the 
particles of interest, visualizes particles resident within the beam using a conventional optical 
microscope aligned normally to the beam axis, and collects light scattered from all particles 
in the field of view.  Videos (60 seconds) were recorded using an electron multiplying 
charge-coupled device, and particle movement was analyzed by NTA software.  Each 
particle was identified and its Brownian movement tracked and measured frame-to-frame. 
The particle movement velocity was used to calculate particle size by applying the Stokes-
Einstein equation. 
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TF and prothrombinase activity.  MPs were pre-incubated with anti-TF antibody (10 µg/mL, 
final) or isotype-matched control IgG (10 minutes, 37 °C) and then with factor VIIa (100 pM, 
final, 5 minutes) and factor X (135 nM, final, 30 minutes, 37 °C), in calcium (5 mM, final).  
Factor Xa generation per MP (per number of cell-marker- and Annexin V-positive events) 
was measured by chromogenic substrate cleavage25 and referenced to a standard curve of 
lipidated recombinant human TF (Innovin).  Prothrombinase activity (per Annexin V-
positive events) was measured as described.19  
 
Thrombin generation by calibrated automated thrombography.  MPs (10 µL) and 20 µL 
HBS/BSA were spiked into 70 µL contact-inhibited MDP with anti-TF or control IgG (10 
µg/mL, final) (58% MDP, final).  Thrombin generation was initiated by automatically 
dispensing fluorogenic substrate (Z-Gly-Gly-Arg-AMC) in CaCl2 (416 µM and 16 mM, 
final, respectively), calibrated against wells containing α2-macroglobulin/thrombin complex 
and plasma, and analyzed with Thrombinoscope software v3.0.0.29 (Thrombinoscope BV, 
Maastricht, Netherlands). 
 
Fibrin formation, network structure and clot stability.  MPs were added to re-calcified (10 
mM, final) MDP (88% MDP, final) in the absence or presence of 0.5 µg/mL tPA.  Fibrin 
formation and lysis were measured by turbidity as described.20  Fibrin networks were imaged 
in 10 µm z-stacks (4 stacks/clot) using laser scanning confocal microscopy in the presence of 
Alexa488-conjugated fibrinogen, as described.19,20  Fibrin density was measured by counting 
fibers intersecting a randomly-applied grid, as described.19,20 
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Statistical analysis.  Data are described using descriptive statistics [mean (±standard error of 
the mean) or mean (range), as indicated].  TF-dependent activity (anti-TF versus control IgG) 
and PMP-dependent activity (±PMPs) were analyzed by paired student’s t test.  For all other 
data, Analysis of Variance (ANOVA) with Dunnett’s post hoc test using buffer as the index 
group was used to control type I error.  P<0.05 was considered significant. 
 
3.3  Results 
MPs from platelets and monocytes have a similar size distribution.  We first characterized 
MPs from TRAP, TRAP/convulxin, and A23187-treated platelets, and LPS-treated PBMCs, 
monocytes, and THP-1 cells using flow cytometry with Annexin V- and cell-specific marker 
positivity, the gold standard for MP characterization and enumeration.24  Figure 3.1A shows 
the MP gate (determined by 500 nm and 900 nm Megamix fluorescent beads) from 
representative PMPs from TRAP-stimulated platelets; MP from TRAP/convulxin- and 
A23187-treated platelets appeared similar (data not shown).  M-MP contamination in PMP 
preparations was <5%.  PMP contamination in MP preparations from LPS-treated PBMCs, 
negatively-selected monocytes, and positively-selected monocytes was 45.4±7.4%, 
33.4±8.7%, and 16.6±2.9% of Annexin V-positive events, respectively, likely from platelets 
contaminating monocyte preparations.  M-MPs derived from positively-selected monocytes 
(Figure 3.1B) were used for subsequent experiments.  We also used THP-1-derived MPs 
(THP-MPs) as a platelet-free source of monocytic MPs, as indicated.   
Although flow cytometry detects particles as small as 300 nm, studies indicate MPs 
may be smaller (100-300 nm).26  To explicitly determine MP size we utilized two 
independent techniques:  TEM and NTA.  TEM enables imaging and measurement of  
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Figure 3.1.  M-MPs and PMPs have similar size distributions.  Representative bivariate 
flow cytometry plots (forward and side scatter) of (A) TRAP-derived PMPs and (B) M-MPs.  
(C) TEM of representative TRAP-derived PMPs and M-MPs.  Scale bar is 200 nm.  
 
 
 
 
 
 
 
 
 
 
Table 3.1. Comparison of MP sizes by TEM and NTA. 
 
TEM  (nm, n=3-6) NTA  (nm, n=2) 
Mean Range Mean Range 
M-MP 270 32 227 46 
PMP (TRAP) 220 199 246 69 
PMP (TRAP/convulxin) 290 182 184 4.3 
PMP (A23187) 267 480 233 61 
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individual MP (Figure 3.1C), while NTA enables enumeration and size analysis of fully 
hydrated MPs (from 20-1000 nm) in suspension27.  Both methodologies indicated MPs have 
similar diameters (150-300 nm), regardless of the parent cell (monocytes or platelets), or 
stimulation method (LPS, TRAP, TRAP/convulxin, or A23187) (Table 3.1).  NTA indicated 
LPS-stimulated monocytes generated approximately 60 M-MP/monocyte, and platelets 
stimulated with TRAP, TRAP/convulxin, or A23187 produced approximately 1.0 
PMP/platelet; both were approximately 85-fold higher than that suggested by flow 
cytometry, consistent with reports that flow cytometry detects only a modest proportion of 
MPs27.  However, although NTA can detect fluorescently-labeled placental MPs27, it has not 
been validated for fluorescently detecting M-MPs or PMPs.  Since MP enumeration in prior 
studies of human plasmas utilized flow cytometry, we used flow cytometry-determined 
enumeration in all subsequent assays. 
 
M-MPs, but not PMPs, promote thrombin generation in a TF-dependent manner.  To 
compare inherent functional properties of MPs from platelets and monocytes, we measured 
both TF- and PS-dependent procoagulant activity.  Figure 2A shows TF activity on M-MPs 
(16.7±2.4 pM TF/106 MP) and THP-MPs (2.88±0.8 pM TF/106 MP).  However, PMPs, 
regardless of the agonist used for their derivation, did not support factor Xa generation 
(Figure 3.2A), suggesting PMPs do not express TF.  
We next compared the ability of these MPs to support prothrombinase activity.  
Regardless of the agonist used for their derivation, PMPs had similar prothrombinase activity 
(Figure 3.2B).  PMPs did not support thrombin generation in the absence of exogenous factor 
Va (data not shown), indicating functional, platelet-derived factor Va was not present on  
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Figure 3.2.  M-MPs, but not PMPs, promote thrombin generation in a TF-dependent 
manner.  (A) TF activity (±SEM) was determined by factor Xa chromogenic substrate 
cleavage (n=5).  *P<0.02 by ANOVA versus PMPs.  (B) Prothrombinase activity (±SEM) 
was determined by thrombin chromogenic substrate cleavage (n=3-4).  MP counts were 
determined by Annexin V-positive events in flow cytometry. *P<0.01 by ANOVA versus all 
PMPs.  (C-D) Thrombin generation supported by 5000 PMP/µL or 1000 M-MP or THP-
MP/µL was measured in the presence of anti-TF or control IgG.  (C) Thrombin lag time and 
(D) peak (±SEM, n=3-6).  Data from PMP from TRAP-stimulated platelets are shown; PMP 
from TRAP/convulxin- or A23187-stimulated platelets were similar.  “Buffer” is HBS/BSA. 
TF is 1 pM (Innovin).  *P<0.05 by ANOVA versus buffer controls.  #P<0.05 by paired 
Student’s t test between anti-TF and IgG controls. 
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PMPs.  Similarly, M-MPs and THP-MPs did not support thrombin generation in the absence 
of exogenous factor Va (data not shown).  Flow cytometry indicated M-MPs had higher 
Annexin V mean fluorescence intensity than PMPs (711.0±71.0 versus 418.7±43.8 arbitrary 
units, P<0.002).  Accordingly, M-MPs showed 2.8-fold higher prothrombinase activity than 
PMPs (4382±584 nM thrombin*min-1/106 M-MP versus 1556±189 nM thrombin*min-1/106 
PMP, Figure 3.2B].  Although THP-MPs had lower Annexin V mean fluorescence intensity 
than PMPs (111.8±2.7 arbitrary units, P<0.001), they demonstrated higher prothrombinase 
activity (4807±879 nM thrombin*min-1/106 THP-MP, Figure 3.2B) than PMPs.  These data 
suggest functional prothrombinase activity is not necessarily predicted by Annexin V 
fluorescence intensity, and confirm that M-MP prothrombinase activity was not due to PMP 
contamination in M-MP preparations.   
Given these inherent differences in the nature of procoagulant activity of monocyte 
(TF and PS)- and platelet (only PS)-derived MPs, we compared their ability to support 
thrombin generation in plasma.  We spiked MPs at levels associated with thrombosis in 
humans (1000 M-MP/µL and 5000 PMP/µL)3,5,7,10 into re-calcified MDP and measured 
thrombin generation by calibrated automated thrombography.  PMPs from TRAP-, 
TRAP/convulxin-, or A23187-stimulated platelets slightly but non-significantly shortened 
the lag time and increased the peak over buffer controls (Figures 3.2C-D, data not shown).  
These activities were not blocked by anti-TF antibody, indicating this activity was TF-
independent.  Although MDP was treated with CTI to inhibit contact activation, studies have 
reported time-dependent loss of CTI-mediated contact inhibition.28  Accordingly, PMPs did 
not trigger clotting in factor XI- or IX-deficient plasma (data not shown).  These data are 
consistent with observations that PMP-enriched plasma from healthy donors supports contact  
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Figure 3.3.  M-MPs initiate fibrin formation.  MPs were spiked into re-calcified MDP and 
fibrin formation was followed by turbidity.  (A) Representative fibrin formation curves.  (B) 
Onset and (C) rate of fibrin formation.  For conditions in which clots did not form, onsets 
were censored at 120 minutes and rates at 0 mOD/min.  Data show mean (±SEM, n=4-6).  TF 
is 1 pM (Innovin).  *P<0.0001 by ANOVA versus buffer controls. 
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pathway-driven thrombin generation2, and attribute this finding specifically to the PMP 
fraction.  
In contrast to PMPs, compared to buffer controls, both M-MPs and THP-MPs 
significantly (P<0.001) shortened the thrombin lag time (5.4±0.5 min and 7.5±0.4 min, 
respectively, versus 84.2±4.8 min, Figure 3.2C) and increased the peak (131.5±23.4 and 
45.6±6.9 nM, respectively, versus 3.6±0.8 nM, Figure 3.2D) in a TF-dependent manner.  
These data indicate monocyte-derived MPs initiate thrombin generation in a TF-dependent 
manner, while PMPs support thrombin generation only in the presence of an intact contact 
pathway.  
 
M-MPs promote fibrin formation.  Given differences in PMP and M-MP procoagulant 
activity, we compared the ability of MPs to support fibrin formation by spiking MPs into re-
calcified MDP and following fibrin formation by turbidity.  PMPs from TRAP- (Figures 
3.3A, B), TRAP/convulxin- (data not shown) or A23187- (data not shown) stimulated 
platelets inconsistently triggered fibrin formation after 60 minutes only at the highest 
concentrations tested, and in a TF-independent mechanism.  As in thrombin generation 
assays (Figure 3.2), PMPs did not trigger clotting in contact (factor XII)-deficient plasma for 
up to 120 minutes (data not shown), indicating PMP activity in MDP reflected time-
dependent loss of contact inhibition28.  In contrast, M-MPs and THP-MPs significantly 
(P<0.0001) shortened the onset (Figures 3.3A, B) and increased the rate (Figures 3.3A, C) of 
fibrin formation in a concentration-dependent manner that was completely blocked by anti-
TF antibody (data not shown).  These data indicate M-MPs and THP-MPs trigger TF- 
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Figure 3.4.  M-MPs, but not PMPs, increase fibrin network density.  Clots were formed 
by incubating MPs (5000 PMP/µL and 1000 M-MP/µL, final) in re-calcified MDP 
containing Alexa488-conjugated fibrinogen, and imaged by confocal microscopy.  (A)  
Micrographs of fibrin networks after clots were fully-formed (180 minutes).  (B) Fibrin fiber 
density shown as mean percent positive grids (±SEM, n=3-5). TF is 1 pM (Innovin).   
*P<0.05 by ANOVA versus buffer controls.  
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dependent fibrin production, while PMPs support fibrin formation only in the presence of an 
intact contact pathway. 
 
M-MPs, but not PMPs, increase fibrin network density.  The fibrin formation rate is 
correlated with fibrin network density.19,20  We used laser scanning confocal microscopy to 
compare effects of PMP and M-MPs on network density versus networks produced by the 
background level of contact activation in MDP.  Addition of TRAP-derived PMPs to clotting 
reactions did not significantly alter network density compared to buffer controls (Figure 3.4), 
although fibers appeared slightly more branched in samples clotted in the presence of 5000 
PMP/µL.  TRAP/convulxin- and A23187-derived PMPs similarly had no significant effect 
on network density (data not shown).  Since platelets increase fibrin density via interactions 
between their integrins and the fibrin network20,29, this observation suggests integrin density 
on PMP is lower than on intact platelets and does not sufficiently interact with the fibrin 
network to alter structure.  In contrast to PMPs, M-MPs significantly increased fiber density 
(P=0.001) over controls (Figure 3.4). 
 
M-MPs increase clot resistance to fibrinolysis.  Fibrin network density is positively 
associated with network stability.19,20  To determine the ability of MPs to promote clot 
stability, we spiked MPs into re-calcified MDP in the presence of tPA, and followed fibrin 
formation and lysis by turbidity (Figure 3.5A).  The time to peak and peak turbidity reflect 
the time to maximum fibrin formation and peak incorporation of fibrin into the clot, 
respectively.20  Both M-MPs and THP-MPs shortened the time to peak (P<0.0001, Figure 
3.5B) and increased the peak (P<0.03, Figure 3.5C) turbidity versus control (buffer), whereas  
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Figure 3.5.  M-MPs increase clot resistance to fibrinolysis.  MPs (1000 M-MP or THP-
MP/µL and 5000 PMP/µL) were spiked into re-calcified MDP in the presence of tPA and 
fibrin formation and lysis were followed by turbidity.  (A)  Representative turbidity curves.  
(B)  Time to peak and (C) peak turbidity change.  Data show mean (±SEM, n=4-7).  TF is 1 
pM (Innovin).  *P<0.05 by ANOVA versus buffer controls. 
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PMPs did not enhance fibrin formation over buffer (contact activation), alone.  These data 
suggest monocyte-derived MPs trigger rapid accumulation of fibrin, even in the presence of 
fibrinolytic activity. 
 
PMPs increase thrombin generation and the fibrin formation rate during TF-initiated clotting.  
Our data indicate PMPs support little to no fibrin generation in the absence of a procoagulant 
stimulus (contact activation), consistent with their apparently non-pathogenic presence in 
healthy individuals.2  However, since PMP supported procoagulant activity (Figure 3.2) and 
fibrin formation following contact activation (Figures 3.2-5), and MPs are recruited to sites 
of vascular injury (TF exposure)14-16, we tested the hypothesis that PMPs augment 
coagulation in reactions triggered by TF.  We spiked PMPs into re-calcified MDP, triggered 
clotting with TF (1 pM Innovin or THP-MPs as a model monocyte TF-bearing MP to avoid 
any influence of contaminating PMPs), and followed thrombin generation and fibrin 
formation.  Addition of PMPs from TRAP-stimulated platelets to Innovin-triggered reactions 
shortened the thrombin lag time from 10.4±0.8 to 8.7±0.5 minutes (P<0.01).  PMPs also 
shortened the lag time in 500/µL and 1000/µL THP-MP-triggered reactions from 4.6±0.2 to 
4.0±0.1 minutes, and 3.7±0.6 to 3.2±0.5 minutes, respectively (mean ± SEM, P<0.04).  
PMPs increased the thrombin peak (P<0.05, Figure 3.6A).  These data reflect the ability of 
PMPs to support thrombin propagation, as well positively feedback on the initiation phase.  
Consequently, addition of PMPs to Innovin- or THP-MP-triggered clotting assays 
consistently increased the fibrin formation rate over Innovin or THP-MP, alone (P<0.01, 
Figure 3.6B), and slightly, but non-significantly, shortened the time to peak (Figure 3.6C) 
and increased the peak (Figure 3.6D) turbidity in fibrinolysis assays.  These findings suggest  
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Figure 3.6.  PMPs increase thrombin generation and the rate of fibrin formation during 
TF-initiated clotting.  PMPs were mixed with THP-MPs or Innovin and spiked into re-
calcified MDP, and thrombin generation and fibrin formation were measured.  (A) Peak 
thrombin and (B) fibrin formation rate in the absence of tPA.  (C) Time to peak and (D) peak 
turbidity in the presence of tPA.  Data show mean (±SEM, n=3-4).  TF is 1 pM (Innovin).  
*P<0.02 by Student’s t test versus 0 PMP/µL. 
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that following initiation, PMPs enhance clotting propagation and promote faster fibrin 
growth.   
 
 
3.4  Discussion 
 The presence of circulating, cell-derived MPs in healthy individuals and their 
increased numbers in disease is well-documented; however, their potential mechanistic 
role(s) in hemostasis and/or thrombosis are poorly-defined.  This information gap results, in 
part, from the lack of studies investigating independent procoagulant contributions of pure 
MP populations.  We specifically characterized properties of MPs from isolated platelets and 
monocytes—MP subtypes most frequently implicated in procoagulant/prothrombotic 
disorders.  Our data show TF-bearing MPs (M-MPs, THP-MPs) initiated plasma thrombin 
generation, promoted fibrin formation, and increased fibrin network density and resistance to 
lysis.  In contrast, PMPs did not support plasma thrombin generation or clotting in the 
absence of a procoagulant trigger (contact or TF).  However, following initiation, PMPs 
significantly increased thrombin generation and the fibrin formation rate.  These data support 
findings demonstrating MP-enriched plasma supports thrombin generation2,12, but extend 
these observations to show consequential, functional effects of MPs from specific parent 
cells on fibrin formation and stability.   
Fueled by reports that MPs are smaller (<0.5 µm) than initially reported (≤1 µm)26, 
use of flow cytometry to characterize and enumerate MPs is controversial; the refractive 
index of cellular vesicles appears lower than that of polystyrene beads used to gate MP 
populations by flow cytometry, leading to underestimation of size.30  Our data are consistent 
with reports that NTA detects more MPs than flow cytometry27 due to increased detection of 
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small (<0.5 µm) particles.  However, using NTA and TEM in addition to flow cytometry to 
assess physical characteristics of platelet and monocyte-derived MPs, our data show MPs 
from both cell types, regardless of the agonist used for their derivation, are ~150-300 nm in 
diameter.  These findings support observations that MPs from LPS- and P-selectin-activated 
monocytes are similar in size26, and extend the observations to include similarity with PMPs, 
suggesting cellular mechanisms producing MPs are common between cell types.11  
Nonetheless, MP characterization may be enhanced by continued refinement of methods that 
detect smaller vesicles.30 
Whereas PMPs circulate in healthy individuals, M-MPs are present only in 
prothrombotic disease.  Our findings provide a rationale for different roles of these MPs in 
hemostasis and thrombosis.  Consistent with the role of activated platelets in coagulation 
propagation31, PMPs augmented thrombin generation and fibrin formation only following a 
procoagulant trigger.  Although it is well-accepted that such a trigger may arise in vivo from 
vascular injury that exposes subendothelial collagen or TF, the contact pathway contributes 
to thrombosis in murine models.32,33  Thus, PMPs may promote thrombus propagation 
following TF- or contact-initiated clotting in humans.  In contrast to PMPs, M-MPs 
independently initiated thrombin generation and fibrin formation, and increased fibrin 
network density and stability, stemming from their ability to support both TF and 
prothrombinase activities.  These findings are consistent with previous findings that 
leukocyte-derived MPs promote thrombogenesis, whereas PMPs are a marker of on-going 
thrombosis.18  Together, these data suggest MPs derived from different parent cells uniquely 
contribute TF-dependent and-independent activities that promote thrombus formation and 
growth. 
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 Given reports of platelet TF expression, it is notable that we did not detect TF activity 
in PMPs.  Discrepancies between findings of TF mRNA processing and de novo protein 
synthesis in PAR- or A23187-stimulated platelets in some34,35 but not other36,37 studies have 
been potentially explained by the transient nature of TF expression following platelet 
activation38.  Given the time required for MP production and isolation following platelet 
stimulation (~30 minutes in our study), it is unclear whether the lack of PMP TF reflects a 
lack of platelet TF expression, or that TF is not packaged into PMPs.  Further studies are 
required to resolve this controversy.  Similarly interesting was our finding that M-MPs and 
THP-MPs had greater prothrombinase activity than PMPs.  Since NTA indicated not all MPs 
were detected by flow cytometry, the higher prothrombinase activity of M-MPs and THP-
MPs could indicate higher numbers of small MPs were generated by monocytic cells and 
were therefore present in the prothrombinase assay.  However, NTA and TEM indicated MPs 
generated by monocytes and platelets had similar physical characteristics.  Although high 
lipid concentrations cause an inhibitory effect in prothrombinase assays, testing additional 
MP dilutions confirmed that MP concentrations used in these assays were below 
concentrations that caused this effect (data not shown).  Tracy et al. previously observed 15-
fold higher prothrombinase activity on monocytes than platelets.39  Our findings support and 
extend this observation by demonstrating these differences are not due to different cellular 
surface area.  
 Our study has potential limitations.  First, MP function was analyzed from isolated 
parent cells; MP produced in vivo may possess unique properties.  However, our findings, as 
well as those of others26 indicate similar physical and procoagulant properties of MPs 
isolated from given cell types, suggesting MPs have defined characteristics whether 
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generated in vivo or in vitro.  Second, while we focused on MPs from monocytes and 
platelets, MPs from other parent cells may possess other procoagulant or 
anticoagulant/profibrinolytic properties.40  Since reports suggest circulating CD41-positive 
MPs derive from megakaryocytes41, caution is advised when extrapolating our findings with 
PMPs to CD41-positive MPs in vivo.  Third, we examined M-MP and PMP procoagulant 
activity; however, their impact depends on their ability to be recruited to and retained in, 
clots.  Accumulation of TF-bearing MPs in thrombi but not hemostatic clots42 suggests not 
all circulating MPs contribute procoagulant activity to all clots.  Fourth, even by positive 
selection, we were unable to reduce the level of platelet contamination in M-MP preparations 
to less than 17%.  Therefore, at least some procoagulant activity exhibited by M-MPs may 
derive from contaminating PMPs.  However, we were able to recapitulate activities observed 
in M-MPs with THP-MPs, supporting our conclusion that monocyte-derived MPs exhibited 
both TF and prothrombinase activity in the assays.  Finally, given 10-15% cell death that 
occurred during monocyte/THP-MPs generation, it is possible that a minor population of 
MPs were generated from dying cells.  However, the recent study by Boles et al. (2011)43 
demonstrates apoptosis-derived THP-MPs have procoagulant properties (TF and PS activity) 
similar to those produced by LPS-stimulated cells, and therefore would be expected to 
exhibit similar behavior as LPS-derived MP in our thrombin generation and fibrin formation 
assays.   
In conclusion, MPs from monocytes and platelets exhibit unique procoagulant 
activities; M-MPs initiated the extrinsic pathway, PMPs supported intrinsic pathway-
dependent clotting.  Both MP types contributed to propagation of clotting.  These data imply  
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a pathogenic role for M-MPs, and suggest PMPs exhibit prothrombotic activity once 
initiation has occurred.  It will be important to compare the contributions of MP from 
different parent cells in in vivo thrombosis models. 
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CHAPTER 4:  FACTOR XIII ACTIVITY IS REQUIRED FOR RETENTION OF 
RED BLOOD CELLS IN VENOUS THROMBI 
 
 
4.1  Introduction 
Venous thrombosis is thought to initiate in the hypoxic environment of venous valve 
pockets1,2, where intravascular activation of coagulation triggers thrombin-mediated 
intraluminal fibrin deposition.  The prevailing paradigm asserts that red blood cells (RBCs) 
are incorporated into venous thrombi via passive trapping during fibrin deposition, 
culminating in the production of a fibrin- and RBC-rich venous “red” thrombus.  However, 
little is known about the mechanisms regulating this process, or how the presence of RBCs in 
venous thrombi contributes to thrombus size. 
Fibrinogen is a 340 kDa plasma glycoprotein consisting of 2 Aα chains, 2 Bβ chains, 
and 2 γ chains that circulates at high (2-5 mg/mL) concentrations.  Following activation of 
coagulation, fibrinogen is cleaved by thrombin and polymerized into an insoluble network 
(reviewed in 3,4).  The transglutaminase factor XIII(a) (FXIIIa) produces ε-N-(γ-glutamyl)-
lysine cross-links between residues Q398/399 and K406 in the γ-chain and subsequently 
between glutamine and lysine residues in the α-chain that stabilize the fibrin network.  This 
stabilization is required for critical functions of cross-linked fibrin which:  1) promotes clot 
mechanical stability via its extraordinary extensibility and elasticity, and 2) protects the clot 
against premature dissolution during wound healing.  
Factor XIII (FXIII) is a protransglutaminase that circulates in plasma at ~70 nM and 
consists of two catalytic subunits (FXIII-A) and two non-catalytic subunits (FXIII-B) in a 
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noncovalent, heterotetramer (FXIII-A2B2, Mr 325 kDa).  Essentially all FXIII-A2B2 in plasma 
circulates in complex with fibrinogen.5,6  FXIII-A2B2 is activated by thrombin-catalyzed 
release of a 37-amino acid activation peptide from the N-terminus of the FXIII-A2 subunits7,8 
and calcium-mediated dissociation of the FXIII B subunits from FXIII-A2, yielding activated 
FXIII-A2 (FXIII-A2*).9-11  FXIII activation is accelerated when it is bound to fibrinogen, 
which facilitates dissociation of the regulatory FXIII-B subunits.12-14  However, the residues 
in fibrinogen that mediate these interactions have not been defined. 
The C-terminus of the fibrinogen γ chain is a site for interactions between fibrinogen 
and a myriad of soluble and cell-associated proteins (reviewed in 15).  In particular, 
fibrinogen residues γ390-395 are immediately upstream of the FXIII cross-linking sites on 
the fibrin(ogen) γ-chain, and mediate interactions with the CD11b subunit of CD11b/CD18 
(Mac-1).  Mice with a mutation of this region (Fibγ390-396A) have normal levels of fibrinogen 
and were reported to exhibit normal fibrin polymerization, platelet aggregation and 
hemostasis, do not develop spontaneous hemorrhage, and undergo normal thrombus 
formation following FeCl3-mediated carotid artery injury16.  However, fibrinogen isolated 
from Fibγ390-396A mice does not support CD11b-mediated adhesion of neutrophils or 
macrophages.16  Fibγ390-396A mice have defective clearance of S. aureus16, but are protected 
against auto-inflammatory disorders including autoimmune central nervous system 
disease17,18, inflammatory joint disease19, colitis-associated cancer20, and Duchenne muscular 
dystrophy21, and this protection is thought to stem from the lack of fibrin-driven leukocyte 
responses during inflammation.  In this study, we analyzed the role of fibrinogen residues 
γ390-396 in venous thrombosis.  Our findings indicate fibrinogen residues γ390-396 mediate 
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FXIII-A2B2 binding and activation, and reveal a critical role for FXIIIa activity in venous 
thrombosis.  
 
4.2  Materials & Methods 
Mice.  Fibγ390-396A mice16 and FXIII-A-/- mice22 were independently backcrossed six 
generations to C57BL/6J background.  CD11b-/- mice23, also on a C57Bl/6 background, were 
backcrossed more than seven generations.  All animal procedures were approved by the UNC 
and Cincinnati Children’s Hospital Institutional Animal Care and Use Committees. 
 
Murine venous thrombosis models.  The IVC stasis model was performed on 8-10-week-old 
male Fibγ390-396A, FXIII-A-/- and WT mice as described.24,25  Briefly, anesthetized mice were 
subject to sterile laparotomy and exposure of the IVC.  Side branches were ligated and 
lumbar branches were closed by cautery.  The IVC was separated from the aorta by blunt 
dissection and completely ligated. The IVC stenosis model was performed as described.26  
Briefly, side branches were ligated but no lumbar branches were cauterized.  Stenosis was 
achieved by partial ligation of the IVC using a 30G needle as a temporary spacer during 
ligation, after which it was removed.  Mice recovered with analgesia (buprenorphine, 0.05 
mg/kg, subcutaneous) and were maintained on acetaminophen (6 mg/mL) in their drinking 
water post-surgery.  After 24 hours, mice were anesthetized and blood drawn from the 
suprarenal IVC into 3.2% sodium citrate (10% v/v, final).  Blood samples were centrifuged at 
5,000xg for 10 minutes to prepare platelet-poor plasma (PPP).  Thrombi were separated from 
the vein wall, weighed, and frozen. 
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Thrombus analysis by western blot.  Frozen thrombus samples from WT and Fibγ390-396A 
mice were homogenized in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 
1 mM Na3VO4 and 1 mg/mL leupeptin [Cell Signaling, Danvers, MA]) supplemented with 1 
mM PMSF using a Dounce Tissue Homogenizer (Bellco Glass, Vineland, NJ).  Thrombus 
lysates were kept on ice for 1 hour before centrifugation (7,000xg, 15 minutes) at 4 °C.  
Supernatants were collected and mixed with 6X non-reducing SDS-sample buffer (Boston 
BioProducts, Boston, MA).  Non-reduced samples were used for blotting leukocyte (Ly6G) 
and platelet (CD41) antigens.  For a subset of samples, the cross-linked fibrin enriched pellet 
was dissolved in 8 M Urea containing 40 mM DTT and 12.5 mM EDTA at 55 °C overnight, 
and then mixed with 6X reducing SDS-sample buffer.   
All samples were separated on 4-12% or 10% Tris-Glycine gels (Novex) and 
transferred to PVDF membranes (Invitrogen, Carlsbad, CA).  Membranes were blocked for 1 
hour at room temperature with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE).  
Primary antibodies against Ly6G (rat anti-mouse clone RB6-8C5 from eBiosciences, San 
Diego, CA, 1:1500), CD41 (goat polyclonal from Santa Cruz Biotechnology, Dallas, TX, 
1:500), or fibrin (clone 59D8 generously provided by Dr. Charles Esmon [Oklahoma Medical 
Research Foundation], 1:500) were incubated overnight at 4°C.  After washing, membranes 
were incubated with fluorescence-labeled secondary antibodies for 1 hour at room 
temperature.  Membranes were then washed and scanned using an Odyssey® Infrared 
Imaging System (LI-COR Biosciences) or GE Typhoon FLA-9000 Imager (GE Healthcare, 
Pittsburgh, PA).   
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Thrombus RBC content.  Thrombus lysates were diluted 10-fold in 20 mM sodium phosphate 
(pH 7.4), 150 mM NaCl (PBS) and absorbance was measured at 575 nm. 
 
Measurement of circulating thrombin-antithrombin (TAT) complexes.  Post-ligation TAT 
levels of PPP prepared from IVC blood draws were measured by ELISA (Enzygnost TAT 
microELISA, Siemens Healthcare Diagnostics, Deerfield, IL). 
 
Measurement of plasma thrombin generation.  Plasma thrombin generation was measured in 
6-fold diluted plasma by calibrated automated thrombography, as described.27 
 
Clot retraction assays.  Blood was drawn from mice into 3.2% sodium citrate (10% v/v, final) 
and corn trypsin inhibitor (CTI, 18.3 µg/mL final).  For whole blood clot retraction, blood 
was used undiluted or was diluted 3-fold in HEPES-buffered saline (HBS; 20 mM HEPES 
[pH 7.4], 150 mM NaCl), in the absence or presence of the FXIII inhibitor T101 (Zedira, 0-
200 µM, final), as indicated.  For platelet-rich plasma (PRP) clot retraction, blood was 
centrifuged twice (150xg, 5 minutes) and PRP was collected and used undiluted.  Clotting 
was triggered in re-calcified (10 mM, final) whole blood or PRP by addition of TF (Innovin 
diluted to 1:12,000 [1 pM] final) or thrombin (2 U/mL bovine thrombin, final), as indicated.  
In all experiments, clotting and subsequent retraction proceeded at 37 °C for 90 minutes in 
siliconized glass tubes.  Retracted clots were imaged to determine final percent retraction.  
Serum was collected, and RBCs were measured by directly counting cells on a HV950FS 
Hemavet cell counter (Drew Scientific, Dallas, TX), or by diluting serum 10 to 100-fold in 
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HBS, measuring absorbance at 575 nm, and comparing to a standard curve of diluted RBCs 
enumerated with a Hemavet cell counter.  Retracted clots were also collected and weighed.  
 
RBC washout assay in the absence of platelets.  Blood was drawn from mice into 3.2% 
sodium citrate (10% v/v, final) and centrifuged (250xg, 10 minutes).  PRP fractions were 
separated and processed to platelet-free plasma (PFP, <20 platelets/µL) by sequential 
centrifugation (2000xg for 15 min, followed by 7000xg for 10 min).  The buffy coat was 
removed from the RBC fraction and washed three times in 1.29 mM sodium citrate, 3.33 mM 
glucose, 124 mM NaCl (pH 7.2) with centrifugation (250xg, 5 minutes).  RBCs were 
resuspended in PBS with 0.1% BSA and centrifuged (500xg, 10 minutes) to pack cells.  
Packed RBCs (4 µL) were added for every 100 µL PFP.  Flow cytometry of PFP and washed 
RBCs revealed less than 0.01% and 10% platelet contamination (% of initial platelet count 
by GPIX-positive events) in PFP and RBCs, respectively.  The initial absorbance of RBC-
PFP mix was determined by 50-fold dilution in PBS.  RBC-PFP mix was clotted with TF (1 
pM, final) and CaCl2 (10 mM, final) at room temperature.  After 1 hour, 700 µL HBS was 
added and absorbance at 575 nm was measured and used to calculate percent change from 
initial absorbance. 
 
Isolation of fibrinogen from plasma with glycine precipitation.  PPP was supplemented with 
10 mM PMSF and 5 mM benzamidine (final).  Glycine (165 mg per mL plasma) was added 
and samples were rotated at room temperature for 1 hour.  The precipitate was collected via 
centrifugation and resuspended in HBS before re-precipitation with glycine.  The precipitate 
was resuspended in HBS and fibrinogen concentration measured by absorbance at 280 nm 
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with a Nanodrop 2000 (Thermo Scientific, Waltham, MA), using an extinction coefficient of 
1.506 mL/(mg/cm).  Fibrinogen was assessed by SDS-PAGE.  Samples were stored at -80 
°C. 
 
RBC adhesion assay.  Microfluidic channels (43.5 x 500 µm in cross-section) were coated 
with 10 µg/mL BSA, purified WT fibrinogen, or Fibγ390-396A fibrinogen for 2 hours at room 
temperature and then rinsed with PBS.  Washed, packed RBCs from WT mice were diluted 
100-fold in PBS (~20,000/µL), loaded into channels, and allowed to adhere for 10 minutes 
under static conditions.  PBS was then flowed through the channels at 1000 s-1 for 5 minutes.  
Bright field images of the channels before and after flow were captured on an Olympus IX81 
inverted light microscope with a 40X objective.  Percent adhesion was measured by counting 
cells using ImageJ software. 
 
Mass spectrometry-based identification of FXIII in WT fibrinogen.  Purified fibrinogen was 
reduced and separated on a 10% Tris-Glycine gel.  Bands were visualized by colloidal “Blue 
Silver” stain28, excised, and analyzed by the Michael Hooker UNC Proteomics Center using 
a MALDI TOF/TOF 4800 Mass Analyzer (ABSciex, Framingham, MA). 
 
Detection of FXIII in murine plasma.  PPP was diluted 1:120 in water and added 5:1 to 
reducing SDS-Sample Buffer.  Samples were separated on a 10% Tris-Glycine gel and 
transferred to PVDF membranes.  Western blotting was performed as above, using sheep 
anti-FXIII-A domain primary antibody (Enzyme Research Laboratories, South Bend, IN, 
1:1000). 
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ELISA for FXIII binding to fibrinogen.  Purified mouse fibrinogen (0.029 µM diluted in 
HBS containing 1 mM CaCl2, [HBS/Ca2+]) was coated onto a Corning 96-well high binding 
microplate.  Control wells were coated with HBS/Ca2+ alone.  Wells were blocked with 
HBS/Ca2+ containing 0.1% BSA and incubated with a 1:5 dilution series of Fibrogammin®-P 
(1.95 µM to 0.2 pM).  Wells were probed with sheep anti-human FXIII-A subunit antibody 
(1:1000) and HRP-conjugated donkey anti-sheep secondary (Cappel, 1:10,000).  All 
incubation steps were performed for 1 hour at room temperature and followed by washing 
with HBS/Ca2+ containing 0.5% Tween 20.  ELISAs were developed with SureBlue 
peroxidase substrate (KPL, Gaithersburg, MD) and generation of blue color was monitored at 
600 nm with a SpectraMax 340PC microplate reader.  The maximum rate of substrate 
cleavage was determined using SoftMax software. 
 
Plasma clot formation and detection of FXIIIa and cross-linked fibrin.  PPP from WT and 
Fibγ390-396A mice was re-calcified (10 mM, final) and clotted with TF (1 pM, final).  At 
indicated time points, quencher solution (50 mM DTT, 12.5 mM EDTA, 8 M Urea) was 
added.  Samples were then incubated at 60 °C for 1 hour with occasional agitation.  Samples 
were reduced, boiled, separated on 10% Tris-glycine gels, and transferred to PVDF 
membranes.  Membranes were probed with rabbit anti-human fibrinogen polyclonal 
antibodies (rabbit anti-fibrin(ogen)).  Membranes were then stripped with 10 mM DTT in 7 
M guanidine for 20 minutes at 60 °C and re-probed with sheep anti-human FXIII-A 
polyclonal antibody.  Band intensity (arbitrary units, AU) was measured by densitometry 
using Photoshop CS6 version 13.0.  Bands were normalized to initial intensity at time 0 with 
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the following exceptions:  FXIII-A* was normalized to FXIII-A at time 0, γ-γ dimers were 
normalized to γ chain at time 0, and HMW cross-linked species were normalized to α chain 
at time 0. 
 
Clot retraction of reconstituted human FXIII-deficient blood.  All procedures were approved 
by the UNC and University of Colorado Institutional Review Boards.  Normal and FXIII-
deficient plasmas were prepared from blood drawn from consenting healthy individuals and a 
patient with FXIII-deficiency.  The patient is a 7 year old female with congenital severe 
deficiency of FXIII (<5%) who receives prophylactic FXIII concentrate infusions every 4 
weeks.  The blood sample was obtained before an infusion.  The trough level at that point 
was 14%.  RBCs and platelets were isolated from blood drawn from consenting healthy 
donors into 3.2% citrate (10% v/v, final) and CTI (18.3 µg/mL, final) and centrifuged 
(150xg, 20 minutes).  The PRP fraction was treated with prostaglandin-I2 (50 ng/mL, final) 
and centrifuged (400xg, 20 minutes).  Pelleted platelets were resuspended in Tyrode’s buffer 
(15 mM HEPES, 3.3 mM NaH2PO4 (pH 7.4), 138 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.5 
mM dextrose), allowed to rest for 30 minutes at 37 °C, counted on a Hemavet, and diluted to 
1 million/µL.  After removing the buffy coat, the RBC fraction was washed 3 times with 
CGS buffer (1.29 mM sodium citrate, 3.33 mM glucose, 124 mM NaCl; pH 7.2), centrifuged 
(400xg, 5 minutes), resuspended in HBS, and packed by centrifugation (400xg, 10 minutes).  
Packed RBCs were diluted 2-fold in HBS and counted on a Hemavet.  Plasma-derived FXIII-
A2B2 (Fibrogammin®-P) or HBS was incubated with citrated normal and FXIII-deficient 
plasmas (no CTI) for 10 minutes at room temperature.  Washed platelets (100,000/µL, final) 
and RBCs (4-5 million/µL, final) were combined with plasmas in siliconized wells of a 96-
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well plate containing TF (1 pM, final) and CaCl2 (10 mM, final).  Clot formation and 
retraction was allowed to proceed for 90 minutes at 37 °C.  RBC content of serum was 
measured by absorbance as described above.   
 
Statistical methods.  Descriptive statistics (mean, median, SD, SEM) were calculated for each 
condition, and Lilliefors test was used to assess normality.  Data were compared by student’s 
t test with equal or unequal variance, as appropriate, for experiments with two groups.  
ANOVA was used for experiments with more than two conditions, with Bonferroni or 
Dunnet post hoc tests for between-group comparisons.  
 
4.3  Results 
Thrombi from Fibγ390-396A mice are smaller and have reduced RBC content compared with 
thrombi from WT mice.  Previous studies have shown that Fibγ390-396A mice have normal 
complete blood counts (WBC, RBC, Hg, HCT, platelets), tail bleeding times, thrombin time, 
wound healing, normal levels of circulating fibrinogen, and exhibit normal platelet 
aggregation and fibrin polymerization16.  However, Fibγ390-396A mice have defective 
leukocyte function due to a failure of fibrin(ogen) to engage leukocyte integrin 
CD11b/CD18.16  Therefore, to first identify leukocyte-independent functions of fibrinogen 
residues γ390-396 on venous thrombosis, we used the inferior vena cava (IVC) ligation 
(stasis) venous thrombosis model that produces thrombi independent of leukocyte TF activity 
(29,30 and data not shown).  Surprisingly, thrombi from Fibγ390-396A mice were 50% smaller 
than thrombi from WT mice 1 day after ligation (Figure 4.1A).  Reduced thrombus weight 
was not due to reduced procoagulant activity; plasma from WT and Fibγ390-396A mice had  
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Figure 4.1.  Compared to thrombi from WT mice, thrombi from Fibγ390-396A mice are 
smaller and have reduced RBC content.  (A) Thrombus weights 1-day post-ligation (stasis 
model).  (B) Total RBC content of stasis thrombus lysates, measured as hemoglobin 
absorbance at 575 nm.  Inset: lysate samples.  (C) Correlation of in vivo thrombus weight 
with total RBC content.  Linear regression for all data points shown in red.  (D) Total 
neutrophil content of thrombus lysates, measured by Ly6G antigen.  (E) Total platelet 
content of thrombus lysates, measured by CD41 antigen.  (F) Total fibrin (β chain) antigen of 
thrombus lysates.  (G) Thrombus weights 1-day post-ligation (stenosis model).  (H) Total 
RBC content of stenosis thrombus lysates, measured as hemoglobin absorbance at 575 nm.  
Each dot represents an individual mouse.  Lines are means. 
 
 
 
 
 
 
Figure 4.2.  Procoagulant activity is normal in Fibγ390-396A mice.  (A) Ex vivo plasma 
thrombin generation in WT and Fibγ390-396A mice (n=4-5).  Data are means ± SEM.  (B) 
Circulating TAT levels in WT and Fibγ390-396A mice following thrombus formation (stasis 
model).  Lines are means. 
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similar thrombin generation in vitro (Figure 4.2A), and circulating TAT levels were similar 
in WT and Fibγ390-396A mice following thrombus formation in vivo (Figure 4.2B).  To 
characterize the venous thrombi produced in these mice, we dissolved thrombi and analyzed 
thrombus lysates.  Strikingly, thrombus lysates from Fibγ390-396A mice had significantly 
reduced absorbance at 575 nm (Figure 4.1B), indicating that they contained fewer RBCs than 
WT thrombi.  Furthermore, the RBC content of the thrombus correlated positively and 
significantly with thrombus weight (Figure 4.1C).  Western blots of thrombus lysates showed 
WT and Fibγ390-396A mice did not differ in Ly6G content, a neutrophil marker (Figure 4.1D), 
indicating the differences in thrombus weights were not due to differences in leukocyte 
recruitment or infiltration.  WT and Fibγ390-396A thrombi also did not differ in CD41 content 
(a platelet marker, Figure 4.1E) or total fibrin (Figure 4.1F).  Results in a second venous 
thrombosis model that involves IVC stenosis rather than complete ligation26,31 were similar; 
despite the typical high degree of variability in clot sizes from WT mice, Fibγ390-396A mice 
still displayed significantly reduced thrombus weights and reduced RBC presence in thrombi 
compared to WT mice (Figures 4.1G-H).  Together, these data suggest Fibγ390-396A mice 
produce smaller venous thrombi because of reduced RBC incorporation and/or retention 
during thrombogenesis. 
 
RBCs are extruded from Fibγ390-396A clots during clot retraction, resulting in decreased clot 
weight.  Our in vivo studies suggested that Fibγ390-396A mice had smaller thrombi due to 
reduced RBC content.  We determined if we could recapitulate this phenotype ex vivo with a 
whole blood coagulation assay in which blood was clotted with tissue factor (TF) and CaCl2.  
In this assay, clot formation is immediately followed by platelet-mediated clot retraction,  
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Figure 4.3.  RBCs are extruded from Fibγ390-396A clots during clot retraction, resulting 
in decreased clot weight.  After clot formation, platelet contractile force retracts clots away 
from siliconized tube walls leaving the clots surrounded by serum.  (A) Image of fully 
retracted WT and Fibγ390-396A clots 90 minutes after initiation of clot formation.  (B) Number 
of RBCs present in the serum following clot retraction (n=3).  (C) Wet clot weights 
following clot retraction (n=3).  (D) Correlation of clot weight with clot RBC content.  
Linear curve fit shown in red.  (E) Image of fully retracted PRP clots 90 minutes after 
initiation of clot formation.  (F) Percent retraction of PRP clots (n=3).  (G) Serum RBC 
content of retracted clots containing WT PRP with Fibγ390-396A RBCs and Fibγ390-396A PRP 
with WT RBCs (n=3).  Data are mean ± SEM. 
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which is complete within 60-90 minutes.  Initially, clotting proceeded similarly for both WT 
and Fibγ390-396A blood.  However, compared to WT clots, Fibγ390-396A clots exhibited 
strikingly reduced RBC retention (Figures 4.3A-B), significantly increased clot retraction 
(Figure 4.3A and data not shown), and significantly reduced weight of fully-retracted clots 
(Figure 4.3C).  Consistent with observations in vivo (Figure 4.1C), clot RBC content 
correlated positively and significantly with clot weight (Figure 4.3D).  Loss of RBCs during 
retraction of Fibγ390-396A clots was not due to alterations in platelet-mediated contraction 
because in the absence of RBCs, clot retraction was identical in WT and Fibγ390-396A platelet-
rich plasma (PRP) (Figures 4.3E-F).  RBC extrusion was also not due to a defect in RBC 
function; when we separately prepared PRP and washed RBCs from WT and Fibγ390-396A and 
mixed WT RBCs with Fibγ390-396A PRP and vice versa, RBC extrusion was specifically 
associated with the PRP component from Fibγ390-396A mice (Figure 4.3G).  When WT and 
Fibγ390-396A whole blood were mixed in equal parts, retracted clot weights were intermediate 
between WT and Fibγ390-396A clots (data not shown).   
Since RBCs bind to platelet αIIbβ332,33, we tested the hypothesis that RBC-platelet 
interactions mediated RBC retention in clots.  We prepared platelet-free plasma (PFP) from 
WT and Fibγ390-396A mice, combined these with washed RBCs from WT mice, and initiated 
clotting with TF and CaCl2.  We then manually dislodged fully-formed clots from tube walls, 
added buffer, and measured RBCs released from the clot.  Under these conditions Fibγ390-396A 
clots released more RBCs than WT clots (3.6±0.6 versus 1.3±0.1 % of initial, P<0.02, n=5).  
However, compared to clots formed in the presence of platelets (Figure 4.3G), both WT and 
Fibγ390-396A platelet-free clots released significantly (>10-fold) fewer RBCs.  These data show 
platelet-mediated clot retraction promotes extrusion of RBCs from Fibγ390-396A clots and that  
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Figure 4.4.  RBCs adhere to fibrinogen from WT and Fibγ390-396A mice.  (A) Adherence 
of RBCs to BSA, WT fibrinogen, or Fibγ390-396A fibrinogen before and after application of 
flow with a shear rate of 1000 s-1.  Scale bar is 3 µm.  (B) Quantitation of RBC adhesion after 
application of flow.  Data are mean ± SEM (n=3).  *P<0.009 versus BSA by ANOVA. 
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platelets are not required to retain RBCs in either WT or Fibγ390-396A plasma clots.  Together, 
these findings show defective retention of RBCs in clots made from blood containing the 
mutant (Fibγ390-396A) fibrinogen. 
 
Fibrinogen residues γ390-396 do not bind to RBCs.  Previous studies have shown that RBCs 
bind to fibrin(ogen) via a specific ligand-mediated interaction involving either CD4734 or a 
β3-like integrin35 on the RBC surface, and an unknown motif on fibrinogen.36,37  To test the 
hypothesis that residues γ390-396 comprise the specific motif on fibrinogen that mediates 
RBC binding, we used a microfluidic-based adhesion assay to measure binding of RBCs to 
purified, adherent WT and Fibγ390-396A fibrin(ogen).  Whereas RBCs did not adhere to BSA-
coated microchannels, RBCs adhered to both WT and Fibγ390-396A purified fibrin(ogen) and 
remained bound even when subject to high (1000 s-1) shear wash rates (Figures 4.4A-B).  
Importantly, there were no differences in the percent of RBCs that remained bound to WT 
and Fibγ390-396A fibrin(ogen) (P=1.0).  These data indicate residues γ390-396 do not mediate 
a direct interaction between RBCs and fibrin(ogen). 
 
Fibrinogen isolated from Fibγ390-396A mice has reduced binding to FXIII.  Our findings 
strongly associated the mechanism mediating RBC retention in thrombi with the mutated 
fibrin(ogen); however, prior findings indicated purified fibrinogen from Fibγ390-396A mice was 
expressed at normal levels, contained Aα, Bβ, and γ chains of fibrinogen, expressed both 
normal (γ) and alternatively-spliced (γ’) fibrinogen (data not shown), and polymerized 
normally.16  We speculated that the deficiency in Fibγ390-396A mice stemmed from a disrupted 
interaction between residues γ390-396 and another protein present in plasma.  Therefore, we  
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Figure 4.5.  FXIII-A2B2 does not co-precipitate with Fibγ390-396A fibrinogen.  (A) Blue 
Silver-stained 10% Tris-Glycine gel containing purified fibrinogens from WT and Fibγ390-
396A mice.  Bands indicated with arrows were analyzed by mass spectrometry.  (B) Western 
blot for FXIII-A subunit in purified fibrinogen (Fgn) samples shown in (A) and commercial 
murine FXIII as a positive control.  (C) Relative level of FXIII-A in WT and Fibγ390-396A 
plasmas.  Data are means ± SEM (n=4).  (D) Relative binding curves of plasma purified 
FXIII-A2B2 (Fibrogammin®-P) to WT or Fibγ390-396A purified fibrinogen.  Data are 
normalized means ± SEM (n=4). 
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isolated fibrinogen from WT and Fibγ390-396A plasma by glycine precipitation and used SDS-
PAGE and silver staining to identify unique plasma proteins that co-precipitated with WT, 
but not Fibγ390-396A fibrinogen.  Two protein bands (Mr ~83 and ~76 kDa) were present with 
equal staining intensity in WT but not Fibγ390-396A fibrinogen preparations (Figure 4.5A).  
Mass spectrometry identified these bands as the A and B subunits of FXIII-A2B2, and 
western blotting with an anti-FXIII-A domain antibody confirmed the presence of FXIII in 
purified WT but not purified Fibγ390-396A fibrinogen (Figure 4.5B).  Since Fibγ390-396A mice 
have normal levels of circulating FXIII in plasma (Figure 4.5C), and since FXIII binding to 
WT fibrinogen is well-established, these data suggest plasma FXIII-A2B2 binds fibrinogen 
from Fibγ390-396A mice with reduced affinity.  Binding assays support this hypothesis; 
compared to WT fibrin(ogen), plasma-derived FXIII-A2B2 bound Fibγ390-396A fibrin(ogen) 
with 6-fold weaker affinity (16±4 versus 90±24 nM, respectively, Figure 4.5D).  These data 
suggest FXIII-A2B2 binds to fibrinogen γ chain residues 390-396.   
 
Fibγ390-396A mice exhibit delayed FXIII activation and delayed fibrin cross-linking in plasma.  
The initial characterization of Fibγ390-396A mice showed that purified fibrinogen from these 
mice can be cross-linked by activated FXIII.16  However, these prior experiments were 
performed with low fibrinogen (0.25 mg/mL, 10-fold lower than is found in plasma) and high 
human FXIII-A2B2 (470 nM, 6.7-fold higher than is found in plasma).  These conditions 
would have masked reduced binding affinity.  Therefore, we used TF to trigger clotting in re-
calcified plasma and measured the kinetics of FXIII activation and fibrin cross-linking by 
SDS-PAGE and western blotting.  Compared to WT, plasma from Fibγ390-396A mice exhibited 
5-fold slower conversion of FXIII-A2B2 to FXIII-A2* (58.3±19.2 versus 12.2±2.5 AU/min  
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Figure 4.6.  Compared to WT, plasma from Fibγ390-396A mice exhibits delayed FXIII 
activation and consequently, delayed fibrin cross-linking during TF-initiated 
coagulation.  (A) Representative western blots for FXIII-A during time course of TF-
initiated clotting in WT and Fibγ390-396A plasma.  Activated FXIII (FXIII-A*) appears over 
time as a lower molecular weight band.  (B) Quantitation of FXIII-A* appearance over time 
in blots from (A).  (C) Representative western blots for fibrin(ogen) during time course of 
TF-initiated clotting in WT and Fibγ390-396A plasma showing γ-γ dimer and higher molecular 
weight (HMW) cross-linked species (α-α and α-γ polymers).  (D) Quantitation of γ-γ dimer 
formation over time in western blots.  (E) Quantitation of HMW cross-linked species over 
time in western blots.  Data are means ± SEM (n=5-6). 
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 [x10-3], P<0.04, Figures 4.6A-B).  Since association of FXIII-A2B2 with fibrin(ogen) 
accelerates its activation by enhancing the release of the regulatory B domain38, these data 
are consistent with a loss of binding between FXIII-A2B2 and Fibγ390-396A fibrinogen.  
Accordingly, compared to WT plasma clots, plasma clots from Fibγ390-396A mice exhibited 6-
fold reduced rate of formation of both γ-γ dimers (P<0.0005, Figures 4.6C-D) and higher 
molecular weight species (P<0.004, Figures 4.6C, 4.6E), consistent with the observed delay 
in FXIII-A2* generation.  Notably, the time course of fibrin cross-linking in these 
experiments mirrors the time frame during which RBCs were extruded during in vitro clot 
retraction.  Together, these data demonstrate a novel defect in FXIII-A2B2 activation and 
activity in Fibγ390-396A mice and suggest decreased FXIII activity permits RBC extrusion 
during clot retraction, resulting in smaller thrombi.  
 
FXIII-deficient mice have reduced RBC retention following clot retraction ex vivo and 
smaller thrombus weights following IVC ligation.  To determine whether FXIIIa activity 
mediates RBC retention during clot retraction, we measured RBC retention during clot 
retraction in whole blood from mice deficient in the FXIII catalytic A subunit (FXIII-A-/-)22.  
For these experiments, we triggered clotting in re-calcified blood with the addition of bovine 
thrombin, and measured clot retraction and RBC extrusion.  Strikingly, whole blood from 
FXIII-A-/- mice exhibited reduced RBC retention during clot retraction, phenocopying that 
seen in Fibγ390-396A clot retraction (Figures 4.7A-B).  In contrast, whole blood from CD11b-/- 
mice23 – the molecular interaction previously shown to be deficient in Fibγ390-396A mice16 – 
had normal RBC retention during clot retraction (Figure 4.7C).  These results strongly 
suggest an essential role for FXIII activity in mediating RBC retention within murine clots.   
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Figure 4.7.  FXIII-deficient mice retain fewer RBCs after clot retraction, and RBC 
extrusion from clots can be induced in normal blood with FXIII inhibition.  Serum RBC 
content following thrombin-initiated clot retraction of re-calcified blood from:  (A) FXIII-A-/-
, (B) Fibγ390-396A, and (C) CD11b-/- mice (n=4-7).  Data are mean ± SEM.  (D) Thrombus 
weights 1-day post-ligation (stasis model).  Lines are medians.  (E) Total RBC content of 
stasis thrombus lysates, measured as hemoglobin absorbance at 575 nm.  Each dot represents 
an individual mouse.  Lines are means.  (F) Correlation of thrombus weight with RBC 
content.  Linear regression shown in red. 
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To examine the effect of FXIII on thrombus formation in vivo we performed the IVC 
ligation stasis model on FXIII-A-/- mice and WT controls.  Similar to that seen in Fibγ390-396A 
mice (Figure 4.1A), FXIII-A-/- mice had significantly reduced thrombus weights compared to 
WT controls (Figure 4.7D).  Moreover, thrombi from FXIII-A-/- mice had significantly fewer 
RBCs than WT controls (Figure 4.7E).  Although some WT controls also produced small 
thrombi, the RBC density of these smaller thrombi was similar to larger thrombi from WT 
controls (data not shown).  Importantly, the RBC content of thrombi from both FXIII-A-/- and 
WT mice correlated positively and significantly with thrombus weight (Figure 4.7F).  
Together these data indicate FXIII activity dictates RBC retention in venous thrombi. 
 
Inhibition of FXIII reduces RBC content in clots formed in human whole blood.  To 
determine whether plasma FXIII activity is also required for RBC retention in human clots, 
we reconstituted plasma from a FXIII-deficient human patient with washed platelets and 
RBCs from healthy individuals.  Reactions were performed in the absence and presence of 
exogenous plasma-derived FXIII-A2B2 (Fibrogammin®-P) added at doses recommended for 
prophylaxis (10 IU/kg, 0.15 IU/mL) and surgery (33 IU/kg, 0.5 IU/mL), and a dose to return 
FXIII-A2B2 levels to normal (67 IU/kg, 1 IU/mL).  FXIII-deficient clots exhibited reduced 
RBC retention following clot retraction, to a similar degree as FXIII-A-/- and Fibγ390-396A 
mice.  Importantly, RBC retention in FXIII-deficient human plasma was corrected by 
addition of FXIII-A2B2 in a dose-dependent manner (Figure 4.8A).  These results 
demonstrate an essential role for FXIII activity in mediating RBC retention in both mouse 
and human clots. 
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Figure 4.8.  FXIII-deficient humans retain fewer RBCs after clot retraction, and RBC 
extrusion from clots can be induced in normal human blood with FXIII inhibition.  (A) 
Serum RBC content following TF-initiated clot retraction of human FXIII-deficient patient 
plasma reconstituted with washed platelets and washed RBCs from normal donors and 
treated with increasing doses of FXIII (0-1 U/mL, n=3-6).  Data are means ± SEM. *P<0.02 
versus FXIII-deficient plasma with no additional FXIII by ANOVA.  (B) Serum RBC 
content following TF-initiated clot retraction of normal human whole blood in the presence 
of the irreversible FXIIIa inhibitor, T101 (0.1-5 µM, n=5).  Data are normalized means ± 
SEM. *P<0.02 versus absence of T101 by ANOVA. 
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Finally, we tested the hypothesis that blocking FXIII activity reduces RBC retention 
and clot size.  We treated normal human whole blood with the irreversible FXIII active site 
inhibitor, T101, and induced clot formation and retraction.  Following clot retraction, the 
baseline levels of RBCs present in serum exhibited inter-individual variability (44.7% CV); 
however, for all donors T101 produced a dose-dependent increase in serum RBC content 
(Figure 4.8B), resulting in a 46±8% reduction in clot size at 5 µM T101.  Moreover, the IC50 
for T101 was 0.43±0.2 µM, consistent with the reported IC50 for FXIII inhibition.39  
Together, these data show FXIII activity is a major determinant of clot RBC content and clot 
size in mice and humans.   
 
4.4  Discussion 
Although the defining characteristic of venous thrombi is their prominent RBC 
content, little is known about mechanisms that mediate the incorporation or retention of 
RBCs in venous clots.  The prevailing view has been that RBCs are sterically trapped by the 
fibrin network during thrombogenesis; however, this premise neglects the dynamic nature of 
a growing thrombus which reflects both biochemical (fibrin deposition) and biophysical (clot 
retraction) processes.  In this study, we identified critical residues in the γ chain of fibrinogen 
that mediate fibrinogen’s interaction with FXIII, and show this interaction is required for 
appropriately-timed FXIII activation and fibrin cross-linking.  We further demonstrate that 
early FXIII activation is required to retain RBCs in clots during platelet-mediated clot 
retraction.  Importantly, we show that loss of FXIII activity results in the formation of 
smaller thrombi via decreased RBC retention in clots.  These novel findings show that RBCs 
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are retained in venous thrombi by a specific, active mechanism that contributes to both 
venous thrombus size and composition.   
Essentially all FXIII-A2B2 circulates bound to fibrinogen5, and following activation, 
FXIII-A2* cross-links intermolecular residues between both the γ and α chains of fibrinogen.  
These observations suggest multiple points of interaction between FXIII and fibrinogen; 
however, the identity of the fibrin(ogen) residues mediating these interactions has been 
elusive.  Older studies suggested FXIII-A2B2 binds preferentially to a minor species of 
circulating fibrinogen produced by alternative-splicing of the fibrinogen γ chain (termed 
γ’)40,41; however, studies with recombinant fibrinogens demonstrated FXIII-A2B2 binds to γ- 
and γ’-containing fibrinogen molecules with similar affinity (KD ~40 nM).42  Smith et al. 
showed high affinity binding of FXIII-A2B2 to a peptide containing amino acid residues 371-
425 of the fibrinogen αC domain (KD 5-30 nM).43  However, because those authors were 
unable to verify binding of FXIII-A2B2 to the αC region on full length fibrinogen, they 
concluded that the interaction between FXIII-A2B2 and the αC region arises during FXIII 
activation, and that other fibrinogen residues fulfill the carrier function for FXIII-A2B2.  Our 
data show that mutations within fibrinogen residues γ390-396 disrupt the interaction between 
fibrinogen and FXIII-A2B2, suggesting these residues mediate this carrier function.  Given 
that the γ chain residues cross-linked by FXIII (Q398, Q399, and K406) are immediately C-
terminal to residues γ390-396, localization of FXIII zymogen at this site would conveniently 
position FXIIIa for rapid cross-linking following its activation.  Subsequent contributions 
from the αC domain would facilitate cross-linking of α chain residues Q221, Q237, Q328, 
and Q366 immediately following formation of γ-γ dimers.  Thus, one hypothesis consistent 
with available data is that the FXIII-A2B2 binding site is a composite between residues in the 
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Aα and γ chains and that disrupting either of these sites reduces binding.  Alternately, FXIII 
may be “handed off” between the fibrinogen γ chain and the αC domain during its activation 
and activity, such that disrupting this process delays cross-linking and reduces fibrin stability.   
Our data show that mutation of residues γ390-396 delayed, but did not abolish, FXIII 
activation and fibrin cross-linking.  The observed delay in FXIII activation and fibrin cross-
linking (Figure 4.6) was temporally-associated with the timing of clot retraction (60-90 
minutes), suggesting these processes also occur in concert in vivo.  These findings imply the 
timing of fibrin formation, FXIII activation, cross-linking, and platelet-mediated clot 
retraction is precisely orchestrated to promote hemostasis, and that alteration in the relative 
timing of these events leads to the formation of abnormal clots.  It is therefore interesting that 
Fibγ390-396A mice have normal thrombus formation following FeCl3-induced arterial injury16, 
but have significantly reduced thrombus size in a venous thrombosis model.  Arterial 
thrombosis is a rapid event triggered by high TF in high shear.  Consequently, arterial 
thrombi are predominantly composed of platelets, and platelet degranulation may release 
sufficient FXIII-A2 transglutaminase activity to stabilize thrombi even in the absence of 
fibrinogen-bound FXIII-A2B2.  In addition, artery occlusion – which typically occurs within 
8-10 minutes – may precede FXIII activation and/or clot retraction, minimizing differences 
between the vessel occlusion time in WT and Fibγ390-396A mice.  Since both FXIII activation 
and clot retraction likely occur after arterial occlusion, Fibγ390-396A mice may exhibit 
decreased thrombus stability and/or decreased resistance to lysis.  Studies are ongoing to 
probe the consequences of delayed FXIII activation on arterial thrombus stability.    
Fibγ390-396A mice have previously been used to probe the contribution of fibrinogen-
leukocyte integrin αMβ2 interactions to physiological and pathological inflammatory 
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responses.  The current data raise the possibility that the diminished inflammatory 
phenotypes observed in Fibγ390-396A mice are a function of delayed FXIII activation and fibrin 
cross-linking rather than, or in addition to, loss of fibrin(ogen) αMβ2-binding activity.  In this 
scenario, FXIII-A-/- mice would be expected to phenocopy Fibγ390-396A mice following 
inflammatory challenges.  In the context of bacterial infection, Fibγ390-396A mice have a 
compromised antimicrobial host response to S. aureus peritonitis challenge16, and FXIII-
deficient mice have compromised antimicrobial activity following S. pyogenes skin infection 
due to a loss FXIII-mediated cross-linking of bacteria to fibrin clots44.  However, in contrast 
to Fibγ390-396A mice, the infection phenotype in FXIII-deficiency is accompanied by 
increased, not decreased, local leukocyte activity and inflammation44, and in contrast to 
reduced bacterial clearance in Fibγ390-396A mice, FXIII-A-/- mice have peritoneal S. aureus 
clearance kinetics identical to WT mice (unpublished data).  Thus, fibrinogen and FXIII 
likely support host defense through multiple, non-mutually exclusive functions that include 
mechanisms linked to leukocyte activation through αMβ2, as well as transglutaminase-
dependent bacterial entrapment.  Fibγ390-396A mice are significantly protected in inflammatory 
disease settings, including central nervous system autoimmune disease17,18, inflammatory 
joint disease19, and Duchenne muscular dystrophy21.  Fibγ390-396A mice are also protected 
against inflammatory colitis following dextran sodium sulfate (DSS) challenge and from 
colitis-associated cancer (i.e., inflammation-driven colonic adenoma formation).20  At 
present, similar comparable analyses of inflammatory disease progression in FXIII-A-/- mice 
remain to be reported.  However, in patients with either active or inactive inflammatory 
bowel disease, circulating levels of FXIII-A2B2 are significantly lower than that of controls.45  
Reduced FXIII levels have been thought to be a consequence of the disease process and 
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attributed to consumption of FXIII from microthrombi formation or accelerated turnover of 
FXIII, but decreased FXIII activity may also contribute to the disease pathogenesis.  
Consistent with this hypothesis, preliminary studies indicate that unlike the Fibγ390-396A mice, 
FXIII-A-/- mice are not protected from colonic injury, but rather display prolonged colonic 
injury following DSS challenge (J. Palumbo, personal communication).  Additional studies 
are warranted to elucidate the contribution of FXIII and FXIII-fibrinogen interactions to 
these inflammatory disease pathologies.  The present data support the hypothesis that 
fibrin(ogen) can contribute to local inflammation through multiple mechanisms including 
αMβ2 engagement and/or FXIII interactions. 
The finding that FXIIIa activity is required to mediate RBC retention in clots reveals 
a novel role for this enzyme in clot formation and composition.  The established targets of 
FXIII(a) activity are the fibrin γ- and α-chains, and FXIII(a)-mediated cross-linking of these 
fibrin chains imparts critical properties to clots.  Compared to uncross-linked fibers, cross-
linked fibers are thinner and more elastic46,47 and require greater force to rupture.48  
Compared to uncross-linked clots, cross-linked clots have smaller pores, increased network 
density, and a higher viscoelastic storage modulus47 (and reviewed in 6,49).  It is currently 
unclear whether these effects directly mediate RBC retention during clot retraction.  Since 
increasing the TF activity increases fibrin network density50 and RBC retention in WT clots 
(data not shown), fibrin structure partly mediates RBC retention in thrombi. Since RBCs 
largely remained in clots in the absence of clot retraction, deficiencies in fibrin integrity 
needed during clot retraction may permit RBC loss.  For example, uncross-linked fibers may 
extend or even break in response to the contractile forces exerted during clot retraction51, 
enabling RBCs to escape.  It is also possible that RBCs, themselves, become cross-linked to 
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the clot, either to fibrin or other clot-bound proteins or cells.  RBCs have been shown to 
directly bind fibrin(ogen)36,37 (Figure 4.4), though this interaction does not require 
transglutaminase activity and is insufficient to maintain RBCs in retracting clots.  Studies are 
ongoing to determine if RBCs are cross-linked by FXIIIa during clot formation.  
Our findings raise the possibility that current clinical guidelines for identifying FXIII 
deficiency fail to recognize the role of FXIII in determining clot composition, and therefore, 
the relationship between low FXIII levels and bleeding.  While congenital FXIII deficiency is 
rare, acquired FXIII deficiency is considered an under-diagnosed disorder due to the relative 
insensitivity of the standard tests, and the supposition that 5% of FXIII levels are sufficient 
for hemostasis.  However, mounting evidence suggests patients with “mild” FXIII deficiency 
due to heterozygosity or surgery have increased risk of bleeding.52  Accordingly, there is 
considerable controversy regarding the level of FXIII antigen required to maintain 
hemostasis in these patients.  Our finding that FXIII mediates clot composition in a dose-
dependent manner across the FXIII reference range (Figure 4.8) suggests that 1 U/mL FXIII 
levels are required to achieve “normal” FXIII function, and that even mildly reduced levels 
of FXIII can result in the formation of abnormal clots.  In addition, FXIII administration is 
being tested as an adjunct hemostatic approach in patients with hemophilia.53,54  Although 
hemophilic patients are not known to have low FXIII levels at baseline, FXIII infusion may 
accelerate the rates of FXIII activation and fibrin cross-linking, and increase both fibrin 
stability and clot RBC content.  Accordingly, observations that certain hemophilic patients 
experience less-than-expected bleeding55,56 suggest a subset of patients may have a co-
existing polymorphism that alters clot stability, such as the FXIII V34L mutation that 
accelerates FXIII activation.57,58  Studies are ongoing to test this hypothesis. 
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Importantly, our findings have significant implications for treating venous thrombosis 
and accelerating thrombus resolution.  Thrombus burden (size) is associated with increased 
morbidity and mortality after venous thromboembolism.  Large, saddle pulmonary embolus 
is associated with 15% mortality at presentation, and treatments for massive PE involve 
fibrinolytic therapy or surgical embolectomy, both of which are associated with 
complications and high mortality.  Following venous thrombosis, larger reductions in 
thrombus mass (clot-burden change) are associated with decreased risk of recurrent venous 
thromboembolism.59  Consequently, a FXIII inhibitor that can reduce thrombus burden may 
be an attractive thromboprophylactic agent.  Since FXIII activity both increases RBC 
retention in clots and increases clot mechanical stability and resistance to fibrinolysis, this 
approach would be expected to both reduce thrombus burden via decreased thrombus mass, 
and accelerate clot dissolution.  Although total FXIII deficiency is associated with bleeding60, 
Fibγ390-396A mice do not exhibit any bleeding tendency.  Thus, it may be possible to reduce 
venous thrombosis without promoting bleeding by specifically blocking FXIII binding to 
fibrin(ogen).  Given that residues γ390-396 are surface exposed61, this region may be readily 
targeted by antibodies or small molecule inhibitors.  
Finally, although the prevailing paradigm suggests that RBCs are non-interacting and 
only incidentally present in thrombi, several lines of evidence suggest RBCs actively 
promote clot formation and stability.  Elevated levels of RBCs are associated with increased 
risk of thrombosis in patients with polycythemia vera or patients on erythropoietin62-64, and 
increasing the hematocrit decreases the bleeding time in anemic patients.65-69  While this 
effect has been attributed to RBC-mediated margination of platelets within the vessels, 
studies show RBCs support thrombin generation70-72 and suppress plasmin generation.73  
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Consequently, RBCs may directly promote thrombus stability, and therapeutic approaches 
that limit thrombus RBC content may reduce thrombus size and/or stability.  Recently, the 
magnetic resonance longitudinal relaxation time (T1) of experimental venous thrombi was 
used to determine effective timing of thrombolytic therapy.  Notably, the shortest T1 times 
correlated with highest Fe3+ in methemoglobin from lysed RBCs, highest percent of fibrin, 
and greatest response to lysis74, suggesting RBC and fibrin content within thrombi are central 
determinants of thrombolytic success.  Our finding that FXIII activity mediates clot RBC 
presence provides a novel tool for investigating the specific contributions of RBCs to venous 
thrombus formation and stability in vivo.   
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CHAPTER 5:  SUMMARY AND FUTURE DIRECTIONS 
 
 
5.1  Summary & Future Directions 
 Cellular and plasma protein crosstalk is an important feature that can vary between 
arterial and venous vascular beds.  The studies comprised within this dissertation emphasize 
the importance of complementary in vitro and in vivo studies to explore this crosstalk.   
 We investigated the prothrombotic potential and vascular bed-specific effects of 
elevated prothrombin in vivo.  These studies followed up on in vitro work demonstrating that 
elevated prothrombin significantly increases thrombin generation and fibrin formation 
without increasing platelet activation.1,2  In our in vivo study, we found that elevated 
prothrombin significantly increased venous thrombosis, but not arterial thrombosis (Chapter 
2).3 The prothrombotic effects of elevated prothrombin were manifested by increased fibrin 
deposition but no significant increase in platelet accumulation.  These data show that, at least 
in an acute setting, elevated prothrombin would not be expected to contribute to arterial 
thrombosis.  Given that the highest risk of arterial thrombosis seen in humans with elevated 
prothrombin occurred in patients who had other underlying risk factors such as hypertension, 
diabetes mellitus, obesity, and smoking4,5, it would be worthwhile to repeat our in vivo 
studies in mice with these additional risk factors. 
 As sub-cellular particles, microparticle procoagulant activities mirror that of their 
parent cells.  Monocytes produce TF/PS-bearing microparticles (M-MP), whereas platelets 
produce PS-bearing microparticles (PMP).  As a result, while M-MPs affect the initiation and 
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propagation of thrombin generation and clotting via the extrinsic pathway, PMPs affect the 
propagation of thrombin generation and clotting via the intrinsic pathway (Chapter 3).6  
These data imply a pathogenic role for M-MPs, and suggest PMPs exhibit prothrombotic 
activity once initiation has occurred.  Follow up on this work was done in collaboration with 
Jian-Guo Wang and Nigel Mackman.  We found that TF-bearing microparticles from 
pancreatic tumor cell lines increased venous thrombosis in a concentration-dependent 
manner, while pancreatic tumor-bearing mice increased venous thrombosis in only 1 out of 2 
venous thrombosis models.7  The impact of TF/PS-bearing microparticles and PS-bearing 
microparticles on in vivo thrombus development in other settings, such as CVD, would be 
interesting for future studies.  Interestingly, some microparticles have also been shown to 
have fibrinoytic activity.  Microparticles from monocytes, endothelial cells, and tumor cells 
express urokinase- and tissue-type-plasminogen activators.8  The significance of the 
fibrinolytic activity is worthy of further investigation. 
 In Chapter 4, we investigated the role of fibrinogen and factor XIII (FXIII) in venous 
thrombosis.  From studies using mice expressing a mutant form of fibrinogen (Fibγ390-396A) 
and FXIII-deficient mice and humans, we made four important discoveries: 1) we determined 
fibrinogen residues involved in FXIII binding; 2) we discovered that FXIII activity is 
required for retention of red blood cells in venous thrombosis in mice; 3) we demonstrated 
that inhibition or deficiency of FXIII reduces RBC retention and reduces clot size; and 4) we 
have redefined the venous thrombosis paradigm to show that RBC retention in clots is an 
active process and not merely passive trapping.  Together, these observations imply that the 
fibrin(ogen)-FXIII axis are determinants of VTE risk and actively contribute to the 
pathophysiology of VTE.  Clearly, continued research into the prothrombotic nature of 
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RBCs, fibrin(ogen), and FXIII is warranted, with a particular emphasis on the physical and 
biochemical interactions between RBCs, fibrin(ogen), and vascular cells.  Disrupting the 
incorporation of FXIII, fibrin(ogen) and/or RBCs into venous thrombi has high potential 
therapeutic value for reducing VTE and VTE-related sequelae. 
 Given our finding that delayed FXIII activation led to delayed fibrin cross-linking and 
reduced RBC retention in Fibγ390-396A clots, it would be interesting to explore the effects of 
accelerated FXIII activation.  One might expect accelerated FXIII activation to increase RBC 
retention and form bigger clots.  The Val34Leu mutation in the FXIII A subunit allows for 
faster release of the activation peptide, resulting in accelerated activation.9  Surprisingly, this 
polymorphism is associated with moderate protection from myocardial infarction in some 
studies10,11 but not others12,13, and meta-analysis of the literature suggests the Val34Leu 
mutation also provides protection from VTE.14  These studies in humans suggest we do not 
yet fully understand how the kinetics of FXIII activation play a role in the pathophysiology 
of thrombosis and suggest studies of the Val34Leu polymorphism in RBC retention are 
warranted. 
 In conclusion, the studies in this dissertation offer insight into the pathophysiology of 
both arterial and venous thrombosis.  In particular, these studies highlight the context-
dependent mechanisms that drive thrombogenesis, and the importance of understanding 
cellular and plasma protein crosstalk. 
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